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ABSTRACT 
Goblet cells are key contributors to intestinal mucosal barrier function through their role 
in production of mucins and other important secretory products, which include trefoil factor 3 
(TFF3) and resistin like molecule β (RETNLB). Goblet cell mucins show great structural 
heterogeneity but can be broadly classified into neutral and acidic subtypes (chemotypes), which 
can be further classified into sulfomucins or sialomucins based on the presence of terminal 
sulfate or sialic acid groups on the oligosaccharide chains. Sulfomucins and sialomucins vary 
regionally throughout the gastrointestinal tract and changes in their expression have been 
observed in diseases such as inflammatory bowel disease and colorectal cancer. It is likely that 
there is variation in these chemotypes among individuals and that both regional and 
interindividual variation in sulfo- and sialomucins may influence microbial colonization. 
However, quantitative data and a description of interindividual variation in sulfo- and sialomucin 
content in the human colon are lacking. There is an absence of data describing the relationship 
between microbial species and these mucin chemotypes in the human colon. In Chapter 2, we 
begin to fill these gaps in the literature via a pilot study examining sulfo- and sialomucins in the 
healthy human colon and their relationship with sulfate reducing bacteria (SRB). Quantitative 
differences in mucin abundance among specific regions of the colon and individuals are 
described. In addition, we observe that the relationship between these mucin chemotypes and 
SRB is not influenced by location in the colon, but rather by the host. In Chapter 3, we begin to 
identify factors that may contribute to changes in sulfomucin in disease and possibly 
interindividual variation, using human adenocarcinoma-derived LS174T cells, which have a 
goblet cell-like phenotype and produce both sulfo- and sialomucins. We specifically focused on 
the effects of bacterial flagellin, IL-13, and TNFα on the expression of genes encoding the major 
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secretory mucin, MUC2, and Golgi sulfotransfereases, CHST5 and GAL3ST2. In addition, 
expression of sulfomucin and Sulfo Lea antigen, which is synthesized in part by GAL3ST2, was 
examined. Overall, the results indicated that both host and microbial factors influence 
sulfomucin expression, possibly via modulation of CHST5 and GAL3ST2 expression. 
Because goblet cells synthesize and secrete cysteine-rich products, including mucins, 
TFF3, and RETNLB, they may have a high cysteine requirement. Furthermore, they may require 
additional cysteine, which can be catabolized to sulfate, for mucin sulfation. Cysteine is also 
used in the production of other proteins as well as essential molecules including glutathione, 
taurine, and pyruvate. However, high cysteine levels are cytotoxic. Mammals regulate cysteine 
metabolism to maintain levels within a range that is sufficient for synthesis of essential 
molecules but below the level of cytotoxicity through the use of cysteine dioxygenase (CDO), 
which catalyzes the first step in cysteine catabolism. In Chapter 4, CDO expression and 
localization in mouse small and large intestine is examined using immunohistochemical and 
immunofluorescence staining techniques. We observed that CDO is expressed in goblet cells as 
well as Paneth and enteroendocrine cells, which are also members of the secretory lineage, while 
expression was absent in absorptive enterocytes. We postulate that this striking difference in 
CDO expression between the absorptive and secretory cell lineages is due to higher cysteine 
catabolism requirements in goblet, Paneth, and enteroendocrine cells relative to absorptive 
epithelial cells, either to synthesize additional taurine and sulfate or to metabolize excess 
cysteine when cells are not actively synthesizing cysteine-rich secretory products. In Chapter 5, 
we examine the possibility that goblet cells are using CDO to synthesize taurine and determine 
whether inflammatory stimuli alter taurine biosynthesis, using the LS174T cell line as a model. 
There are two pathways for taurine synthesis. One pathway involves the oxidation of cysteine via 
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CDO to cysteinesulfinate, which is decarboxylated by cysteinesulfinic acid decarboxylase 
(CSAD) to hypotaurine. The other pathway involves the conversion of cysteine to Coenzyme A, 
which releases cysteamine during turnover. Cysteamine is then oxidized to hypotaurine via 
cysteamine dioxygenase (ADO). In both pathways, hypotaurine is then oxidized to taurine. We 
confirm that LS174T cells synthesize taurine via the ADO pathway and possibly the 
CDO/CSAD pathway. We also demonstrate that certain inflammatory triggers can enhance 
taurine biosynthesis and/or export, which may provide taurine for other cell types in an in vivo 
setting. The anti-inflammatory effects of taurine in the intestine have been described, so these 
results may represent a novel mechanism by which goblet cells attenuate inflammation. Overall, 
the findings described in this dissertation provide novel information regarding the role of 
intestinal goblet cells in mucosal barrier function. 
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Chapter 1 
LITRATURE REVIEW 
 
INTRODUCTION 
Goblet cells are specialized columnar epithelial cells, which secrete mucins and other 
products that provide critical barrier function for the host and contribute to intestinal 
microhabitats that are colonized by mutualistic microbes [1]. The secreted mucus gel layer is an 
integral structural component of the gut mucosal surface, acting as a medium for protection, 
lubrication, and transport between luminal contents and the epithelial lining of the intestine. 
Without this protective cover, the single-celled layer of epithelium is at constant risk of injury 
from exposure to luminal insults, including chemical irritants, digested food products, toxins, 
resident microbiota, and intestinal pathogens and their products [1]. 
The intestinal epithelium also acts as a barrier limiting interaction between the intestinal 
microbes and immune cells contained in the lamina propria and lymphoid aggregates. The small 
intestinal epithelium consists of absorptive enterocytes and secretory cells, which include the 
mucin-secreting goblet cells, peptide hormone-secreting enteroendocrine cells, and microbicide-
secreting Paneth cells [2]. Goblet cells can be identified by their unique mucus filled theca. They 
are normally found in the crypts of both the small intestine and colon and scattered between the 
absorptive enterocytes in the villi of the small intestine and colonocytes on the surface of the 
colonic cuffs. Goblet cell density in the small intestine increases from duodenum to ileum, but 
enterocytes remain the predominant epithelial cell type, reflecting the largely absorptive function 
of the small intestine [3]. The simple columnar epithelium of the colon also contains absorptive 
cells (colonocytes), goblet cells, and enteroendocrine cells, but Paneth cells are noticeably 
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absent. Goblet cells and colonocytes comprise the majority of the epithelial cell content in the 
colon with goblet cells primarily occupying the colonic crypts and colonocytes making up the 
surface of the colonic cuffs. Goblet cells are found in much greater numbers within the colon and 
their density increases in a proximal to distal manner from the cecum to the rectum [3]. This may 
reflect the increased importance of goblet cells and the secreted mucus layer for host protection 
in more distal regions of the colon. 
 
 
GOBLET CELL DIFFERENTIATION 
The intestinal epithelial cell lineages are thought to arise by mitosis of multipotent stem 
cells that are maintained near the base of the crypts in the small intestine and at the base of the 
crypts in the colon [2]. As the stem cells migrate from crypt to villus in the small intestine and 
from crypt to the surface of the colonic cuffs in the large intestine, they are believed to 
differentiate into progenitor cells, which then further differentiate into the specific epithelial 
lineages. In the small intestine, most differentiation occurs from near the base of the crypt up 
until the crypt-villus junction. At this important junction, goblet cells, enterocytes, and 
enteroendocrine cells continue to migrate up the villi, while Paneth cells migrate down to the 
base of the crypts. Since Paneth cells are not found in the colon, all migration and differentiation 
in this region occurs in the direction from crypt base to lumen. In the case of the human goblet 
cell, migration is completed from small intestinal crypt to villus tip within 4 to 5 days and from 
colonic crypt to the surface of colonic cuffs in approximately 6 days [1]. Upon reaching the 
lumen, the cells may undergo apoptosis and/or be sloughed off into the lumen.  
A considerable amount of progress has been made in elucidating signaling pathways 
involved in intestinal goblet cell differentiation. The Wnt/β-catenin signaling pathway appears to 
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be essential for maintenance of undifferentiated stem/progenitor cells in intestinal crypts and for 
switching from a proliferating progenitor phenotype to a differentiated epithelial cell [2]. Wnt 
target gene expression indicates that the Wnt pathway is active in a gradient with greatest 
activity at the crypt base [4], which is consistent with its reported importance in Paneth cell 
maturation [5].  
The canonical Notch signaling pathway, which regulates cell fate in a number of systems 
through close range cell-cell interactions, plays a key role in epithelial cell lineage determination 
in the intestine by maintaining the proliferative progenitor state of stem cells and limiting the fate 
of cells of the secretory lineage. Disturbance of the Notch pathway results in loss or 
overabundance of goblet cells [6-9]. Inhibition of the pathway in the intestine through removal of 
the transcription factor CSL/RBP-J or use of gamma-secretase inhibitors led to massive 
conversion of proliferative cells into goblet cells in the small intestine and a similar increase in 
goblet cells in the colon [8]. A complementary gain-of-function approach produced the opposite 
phenotype, which exhibited reduced abundance of secretory cells and an expansion of immature 
progenitor cells [9]. HesI, a direct target gene of Notch, represses transcription of the 
transcription factor MathI, which is required for commitment toward the secretory lineage [6]. 
Consequently, Hes1-/- mice show increases in goblet, enteroendocrine, and Paneth cells, while 
MathI-/- mice show depletion of goblet, enteroendocrine, and Paneth cells without affecting 
enterocytes [6, 10]. Gfi1, a zinc-finger transcriptional repressor that appears to function 
downstream of MathI, is involved in the selection of the goblet/Paneth cell lineage over the 
enteroendocrine lineage [11]. The Wnt pathway may also influence cell lineage via effects on 
MathI. Impairment of Wnt signaling decreases MathI-positive precursor cells in the crypt, 
leading to loss of the secretory lineage [12].  
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Bone morphogenetic protein (Bmp) signaling, which was previously identified as a key 
mediator in crypt and villus morphogenesis as well as maintenance of intestinal stem cells, was 
shown recently to also be necessary for terminal differentiation of the secretory lineage [13]. 
Disruption of the Bmp signaling pathway results in smaller, but not fewer, goblet cells with 
immature appearing granules and decreased expression of secretory lineage–specific genes, 
indicating loss of goblet cell terminal differentiation and maturity. These effects may have been 
mediated by decreased expression of the zinc-finger transcription factor, Krüppel-like factor 4 
(Klf4), which was previously identified as being required for terminal goblet cell differentiation 
in the colon [14]. Recently, Klf4 expression was also found to be inhibited by Notch signaling. 
When Notch signaling was inhibited, Klf4 expression and goblet cell numbers increased [15]. 
CDX2, a member of the caudal-related homeobox gene family, has anti-proliferative 
effects on intestinal epithelial cells and regulates transcription of both enterocyte and goblet cell 
specific genes [16-21]. In the case of goblet cells, CDX2 transactivates the promoters of genes 
encoding goblet cell secretory products, including mucin 2 (MUC2), resistin-like molecule beta 
(RETNLB or RELMβ), and trefoil factor 3 (TFF3) [19, 21, 22]. CDX2 was also reported to 
activate expression of KLF4 and modulate the notch signaling pathway, indicating that CDX2 
has an important role in mature goblet cell development and function on multiple levels [23, 24].  
 
 
GOBLET CELL SECRETORY PRODUCTS 
Mature goblet cells are unique in their synthesis and secretion of a number of products 
including specific mucins, TFF3, and RELMβ. These products are important in the maintenance 
of intestinal barrier function. The most recognized contribution of goblet cell secretory products 
5 
 
is the formation of the mucus gel layer that overlays the intestinal epithelium and forms a 
selective barrier between the host and the luminal contents.  
 
 
MUCINS 
Mucus is a heterogeneous mixture of secretions comprised of approximately 95% water 
and containing electrolytes (Na+, K+, Mg2+, and Ca2+), carbohydrates, proteins, amino acids, and 
lipids [25]. The viscoelastic, polymer-like properties of mucus are derived from the major gel-
forming glycoprotein components called mucins [1]. Mucins consist of a peptide backbone 
containing alternating glycosylated and nonglycosylated domains, with glycosylated regions 
comprising 50 to 90% of the polymer. The peptide backbones of mucins are encoded by the 
MUC family of genes [26, 27]. Mucins can be categorized as secreted or membrane-bound. 
Membrane associated mucins are bound to cells by an integral transmembrane domain found in 
their carboxy terminus and appear to be important in signal transduction. Secreted mucins are 
released from cells and are further classified into gel-forming (MUC2, MUC5AC, MUC5B, 
MUC6) and non-gel-forming mucins (MUC7). The gel-forming mucins contain cysteine-rich 
motifs in their C- and N-terminal domains necessary for oligomerization and formation of a 
protective mucus gel [28].  
MUC2, which is secreted exclusively by goblet cells, is the major secretory mucin of the 
small intestine and colon [29]. Structurally it consists of two central tandem repeat domains rich 
in serine, threonine, and proline that serve as potential O-glycosylation sites and multiple 
cysteine-rich domains that are not glycosylated. The cysteine-rich domains include four von-
Willebrand-factor (VWF) D-like domains, a VWF-C-like domain, a C terminal domain with 
similar topology to a cystine knot motif, and two cysteine-rich domains that flank the first 
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tandem repeat domain [26, 29]. Oligosaccharide side chains are linked to the mucin peptide core 
by O-glycosidic bonds between threonine or serine on the peptide core and N-
acetylgalactosamine (GalNAc) on the sugar chains [30]. The oligosaccharide chains typically 
occur in clusters along the polypeptide with the amino and carboxyl terminal ends being less 
glycosylated [31]. The clusters of O-linked oligosaccharide chains provide the mucins with 
regions that are protease resistant and highly hydrated, which is important in protecting the 
mucins from degradation and for lubricating the epithelium [31]. 
The composition of the mucin oligosaccharide chains is highly variable, contributing to 
the heterogeneity of mucins and thus the mucus layer. The structure of an oligosaccharide chain 
can be described according to the core sequence directly linked to the peptide, the backbone (not 
always present), and the peripheral region, which is made up of sialic acid, blood group antigens, 
or ester sulfate substitutions [31]. There can be a number of variations in each of these 
components including sugar type, chain length, and degree of branching. Termination of mucin 
oligosaccharide chains with sialic acid or sulfate groups accounts for the polyanionic nature of 
mucins at a neutral pH [1, 30]. These variations likely alter the biological and physiological 
properties of the mucins and affect which bacteria are able to colonize the mucus layer. 
Carbohydrates and terminal groups on mucin oligosaccharide chains can serve both as binding 
sites and as a potential source of nutrients for microbes. A number of interactions between 
microbes and mucins have been demonstrated in the colon and other mucosal regions of the body 
[32, 33]. However, there are likely many more that remain to be characterized. 
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MUCIN BIOSYNTHESIS 
The biosynthesis of a secreted mucin is a complex process that requires a number of steps 
including translation of the MUC gene, folding and dimerization of the peptide, O-glycosylation, 
polymerization and storage [34]. In line with the central dogma, MUC genes are first transcribed 
in the nucleus to produce MUC transcripts, which are translated into MUC proteins on 
endoplasmic reticulum (ER)-associated ribosomes. Post-translationally, mucins are folded, N-
glycosylated and form disulfide-linked dimers in the ER before being modified by one or several 
glycosyltransferases in the Golgi [28, 34]. Most O-glycosylation occurs in the cis-Golgi 
beginning with the transfer of GalNAc from UDP-GalNac by an N-acetylgalactosaminyl 
peptidyltransferase to a serine or threonine in the tandem repeat domains. The addition of 
GalNac to a serine or threonine on a nascent mucin peptide forms what is known as the Tn 
antigen. Elongation of each O-glycan is accomplished by the stepwise addition of galactose 
(Gal), N-acetylglucosamine (GlcNAc), fucose, or sialic acid from nucleotide sugar donors by 
specific glycosyltransferases in the Golgi [28, 31]. 
Eight different core structures linked to the mucin peptide have been identified, but cores 
1-4 are found most commonly in mucins throughout the gastrointestinal tract (Table 1.1) [31]. 
The core 1 subtype is formed by the addition of Gal in a β1-3 linkage to GalNac. Subsequent 
glycosyltransferases can elongate the core 1 structure or convert it into the core 2 subtype by the 
addition GalNac. The core 3 subtype, which is predominant in normal colonic tissue, is 
generated by adding GlcNA to GalNAc and can be branched with the addition of GlcNac to form 
core 4. The core structures can be elongated by Gal and GlcNAc transferases to form 
Galβ1,3/4GlcNAc units. O-glycan synthesis is terminated by the addition of fucose, Gal, 
GalNac, and sialic acid via an α-glycosidic linkage, which prevents further elongation and gives 
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rise to the ABH and Lewis blood group antigens. Sialic acid moieties and sulfates are transferred 
to Gal or GlcNAc moieties and impart negative charges to mucins. To add another dimension of 
heterogeneity, sialic acid residues may be mono- or poly-O-acetylated [34, 35]. Mature, fully 
glycosylated, mucins are sorted and packaged into secretory granules where they are stored until 
regulatory signals trigger granule exocytosis [1]. 
Sulfation occurs within the trans-Golgi as a late step in glycoprotein synthesis when 
specific sulfotransferases transfer sulfate from 3′ -phosphoadenosine 5′-phosphosulfate (PAPS) to 
mucin O-glycans at the C-3 position of galactose residues or the C-6 position of N-
acetylglucosamine [36, 37]. Of the four galactose 3-O-sulfotransferase (GAL3ST) genes that 
have been described, GAL3ST2 appears to be the sulfotransferase responsible for sulfate 
addition to the C-3 position of Gal in human colonic mucins [38]. GAL3ST2 expression is 
downregulated in non-mucicnous adenocarcinomas, which corresponds with the lower 
expression of sulfomucin seen in this type of colonic adenocarcinomas [38]. Of the known N-
acetylglucosamine-6-O sulfotransferases, CHST5 (GlcNac6ST-3) is the only one that shows 
specificity for the intestine and is the most abundant of the N-acetylglucosamine-6-O 
sulfotransferases in the human colon and small intestine [39, 40]. In addition, CHST5 shows a 
preference for sulfating O-linked chains of the mucin-type [39], suggesting that it is involved in 
transfer of sulfate to the C-6 position of N-acetylglucosamine in sulfomucins. Furthermore, like 
GAL3ST2, CHST5 expression is downregulated in colonic adenocarcinomas [38]. 
 Sialic acid can be obtained from the diet or can be synthesized endogenously from 
glucose or other products of glycolysis [41, 42]. Synthesis of sialic acid occurs in the cytosol, but 
it is transferred to the nucleus to be converted to its active form, cytidine monophosphate-N-
acetylneuraminic acid (CMP-Neu5Ac), by CMP-NeuAc synthetase (CMAS) [42, 43]. Sialic acid 
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is transferred from CMP-Neu5Ac to mucin O-glycans in the Golgi by sialyltransferases. 
However, unlike the sulfotransferases, sialyltransferases acting on O-glycans can be found 
distributed from cis-Golgi to trans-Golgi [44]. This is important because sialyltransferases can 
compete with enzymes involved in core structure formation for certain substrates and addition of 
sialic acid can prevent further elongation of an O-glycan. Thus, if a sialyltransferase is localized 
in an earlier compartment of the Golgi, it may prevent synthesis of core structures, resulting in 
short, sialylated O-glycans [36, 44]. In most oligosaccharides, the sialic acids occur as peripheral 
residues in alpha-2-3 and alpha-2-6 linkages [34]. The sialyltransferases that appear to be 
particularly important for colonic mucins are ST6 beta-galactosamide alpha-2,6-sialyltranferase 
1 (ST6GAL1) and ST3 beta-galactoside alpha-2,3-sialyltransferase 4 (ST3GAL4) [45]. Sialic 
acids in colonic mucins are commonly O-acetylated at positions C4, 7, 8, or 9 [34]. This occurs 
by transfer of an O-acetyl group from acetyl-CoA by action of an O-acetyltransferase [36]. O-
acetylation of sialomucins changes their physical properties and appears to confer resistance 
against bacterial degradation. 
 
 
GOBLET CELL MUCINS IN NORMAL HUMAN SMALL INTESTINE AND COLON 
 Goblet cell mucin O-glycans can be analyzed using various methods, including 
histochemisty [35, 46], lectin histochemistry [47], immunohistochemistry [48], metabolic 
labeling [49], chromatographic methods, mass spectrometry [37, 50], and NMR [37]. While 
chromatographic and spectroscopic methods can provide much more structural detail, they lack 
the ability to provide information about localization that can be achieved with histochemical and 
immunohistochemical techniques. Conventional histochemical methods can be used to classify 
mucins as neutral or acidic mucins, which can be further classified into sialomucin or sulfomucin 
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[35]. The periodic acid Schiff (PAS)/Alcian blue (AB)  pH 2.5 stain can be used to distinguish 
neutral and acidic mucins depending on whether they stain the PAS-positive magenta (neutral), 
AB-positive blue (acidic), or PAS- and AB-positive purple (mixed acidic and neutral mucins). 
The high iron diamine (HID) Alcian blue (AB) pH 2.5 stain can be used to distinguish 
sialomucins (blue) and sulfated mucins (brown/black).  
 Regional and spatial differences in intestinal goblet cell mucins based on histochemical 
staining have been previously described. A summary of typical patterns observed for neutral, 
sialo-, and sulfomucins in the small intestine and colon is shown in Figure 1.1. Goblet cells in 
the normal small intestine primarily synthesize and secrete neutral mucins and sialomucins, but 
few sulfated mucins are found in the ileum near the ileocecal junction [35, 51]. The distribution 
of neutral and sialomucins varies from crypt to villus with goblet cells located in the crypts 
predominantly producing neutral mucins and those along the villi producing sialomucins [51, 
52]. This distribution also appears to correlate with goblet cell differentiation and development, 
indicating that more mature goblet cells in the small intestine express sialomucin [52, 53]. 
Regulation of mucin composition by pathways involved in goblet cell differentiation, however, 
remain to be examined. O-acetylated derivatives of sialic acid become more apparent in moving 
from the duodenum to ileum, and the ratio of sialic acid to fucose increases. This observation 
along with the appearance of sulfomucins in the distal ileum suggests a gradual transition from 
small intestine to colon, which contains more O-acetylated sialomucin and sulfomucins. Robbe 
et al (2004) also demonstrated that a number of gradients exist in moving from the ileum to the 
rectum and provided additional insight into the composition of ileal mucins using a combination 
of NMR spectroscopy, gas chromatography, and MALDI-MS. They reported that mucins in the 
ileum contain the largest oligosaccharides and these are predominantly neutral and highly 
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fucosylated [37]. In an earlier study, they also reported a decreasing gradient of fucose and ABH 
blood group expression from ileum to rectum [50]. An increasing acidic gradient was observed 
in associated with an increase in both 3-O-sulfated Gal and sialic acid. This observed gradient 
correlates with histochemical data obtained for the normal colon.  
Normal colonic goblet cell mucins contain neutral mucins, sialomucins, and sulfomucins 
with sulfomucins predominating. Both N- and O-acetylated sialic acids are present and these may 
include derivatives which are mono-, di, or tri-acetylated. The mucin pattern varies both 
regionally and along the crypt-surface axis, again paralleling cellular differentiation. Decreased 
PAS-reactivity is found moving from cecum to rectum indicating a proximal to distal decrease in 
neutral mucins. Neutral mucins may be found in moderate amounts in the upper crypts and to a 
lesser extent in the lower crypt.  In the cecum and ascending (or right) colon, sialomucins are 
found in goblet cells in the lower third of the crypt and a few along the surface epithelium while 
sulfated goblet cells predominate in the upper crypt region [35]. A different pattern is observed 
in the left colon where goblet cells containing sulfated mucins are found in the lower half of the 
crypt and a variable number of sulfomucin and sialomucin containing goblet cells are contained 
in the upper half of the crypt [35]. In the rectum, a greater portion of the upper crypt appears to 
contain sialomucins and a number of goblet cells containing a mixture of both sulfated and sialic 
acid containing mucins are found [35, 54]. Thus, both the sialomucin content and heterogeneity 
of mucins appears to increase in moving from the left colon to the rectum. While these general 
patterns in mucin chemotype expression have been reported, few studies have examined 
interindividual variation in mucin composition.  
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MUCINS AND INFLAMMATORY BOWEL DISEASE 
 It has been known for many years that alterations in mucins and the mucus layer occur in 
a range of gastrointestinal diseases, including adenocarcinomas and inflammatory bowel disease 
(IBD).  In the case of IBD, changes in the thickness of the mucus gel layer, goblet cell number 
and intracellular mucin content, and mucin glycosylation have all been reported [55-58]. Defects 
in mucins may contribute to the chronic inflammation seen in Crohn’s disease and ulcerative 
colitis by facilitating a breach of the epithelial barrier or altering mucosal-bacterial interactions 
[55]. Another possibility is immunological or bacterial factors that are altered in response to 
initial or ongoing inflammation affect mucin production, which then leads to perpetuation of the 
inflammation. 
 The thickness of the mucus layer appears to be a distinguishing feature between CD and 
UC. Pullan et al. (1994) described a decrease in the thickness of the mucus layer of UC patients 
and an increased thickness in the mucus layer covering the rectum in CD patients compared with 
the rectum of normal subjects [59]. A reduction in the area of epithelium covered by mucus in 
the sigmoid colon of UC patients compared to normal sigmoid colon was also described by 
Swidniski [58]. Recently, the thickness and continuity of the adherent mucus layer of the rectum 
were assessed in patients with rectal CD and different grades of UC [57]. Significant differences 
were not seen in the thickness of the mucus layer between normal subjects and subjects with 
inactive, mild or moderate UC, but a significant difference was observed between healthy 
subjects and subjects with severe UC. The percentage of the mucus layer that was discontinuous 
was significantly increased in active UC, and this discontinuity appeared to increase with 
severity of UC. The decrease in mucus thickness and continuity may have been the result of 
reduced goblet cell density, which was found to be especially apparent in severe UC [57]. In the 
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case of CD patients, the thickness and continuity of the mucus layer and goblet cell number were 
unaltered when compared with controls. This is in contrast to the results of Pullan and coworkers 
(1994) and may reflect the stage and type of CD, differences in the preservation of the adherent 
versus the loose layer of mucus, or the small number of specimens examined.  
 Alterations in mucin glycosylation that have been described in IBD include decreased 
length of the mucin oligosaccharide chain, decreased sulfation and O-acetylation of sialic acid, 
increased sialylation, and increased expression of the TF and sialyl-Tn antigens [55, 56, 60]. 
Both metabolic labeling and HID/AB staining have demonstrated a significant loss of mucin 
sulfation in UC [61, 62], which appeared to correlate with severity of disease. Van Klinken et al. 
provided further insight into this phenomenon and reported that while MUC2 is undersulfated, 
sulfated MUC2 is selectively secreted [49]. Furthermore, the decrease in secreted MUC2 is 
likely due to decreased MUC2 production rather than just a decreased in secretion since the 
percent secreted did not change. Intriguingly, upon remission the number and appearance of the 
goblet cells return to normal, indicating that the goblet cell changes are observed only during 
active inflammation. This suggests that the observed mucin changes are not a cause of the 
inflammation but a consequence. However, a study comparing mucin sulfation in European and 
South Asian patients with UC suggests the role of a genetically determined abnormality in 
glycosylation [63]. Staining of rectal biopsies from South Asian colitics revealed a high degree 
of sulfation, resembling normal human rectal tissue, irrespective of disease activity. On the other 
hand, biopsies from European colitics, showed decreased sulfation and increased sialylation with 
increased disease activity. These findings are particularly interesting given that South Asians 
have a reduced risk of severe colitis and colorectal cancer [63].  
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 The loss of sulfation and increased appearance of sialomucin that is observed in UC is 
not considered to be a feature of CD. However, both Ehsanullah and Allen described an 
abnormal predominance of sialomucins in the majority of rectal biopsies collected from CD 
subjects [64, 65]. Attempts were not made in these studies to score disease severity in CD 
patients. There is also some evidence using metabolic labeling that sulfation is decreased in 
rectal biopsies from CD patients [62]. The observed reduction did not reach statistical 
significance, but this may have been due in part to the small sample size (n=6 for CD and n = 16 
for controls).  
 Expression of the TF antigen, which is a reflection of abnormal glycosylation, occurs in a 
portion of UC and CD subjects [60]. The presence of this antigen was examined in monozygotic 
UC and CD twins and unaffected monozygotic twins of UC and CD patients. Positive staining 
for the antigen using peanut lectin histochemistry was found among all 22 affected monozygotic 
twins with IBD and nearly all (15/16) unaffected twin siblings of IBD patients. Staining was 
localized in the supranuclear region plus a variable degree in the glycocalyx and secreted mucus 
layer. About ¼ of the control subjects also showed positive staining, but staining only localized 
to the supranuclear region. A strong correlation was seen between PNA positivity and NFκB 
activation, indicating a relationship to inflammation. Overall, the study indicates that the changes 
in glycosylation may be the result of a genetically predisposed individual being exposed to an 
environmental trigger [60]. 
 
MICROBIAL AND HOST MODULATION OF MUCIN COMPOSITION 
Although decreased sulfation of mucins has been associated with active inflammation in 
human IBD, the underlying causes and the relationship to disease pathology remain undefined. 
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Both animal and in vitro studies demonstrate that mucin chemotype may be altered by changes in 
the normal microbiota and inflammation [33, 66-69]. The evidence for microbial modulation of 
mucin chemotypes comes from developmental studies and those comparing conventionally-
raised and germfree rodents. In mice, for example, the temporal development of sialo- and 
sulfomucin chemotypes in the colon appears to parallel the establishment of microbial 
communities and is not observed in germfree mice, in which crypt mucins remain predominantly 
sulfated [33, 70]. Specific microbial components or products may be responsible for the 
observed effects of the microbiota on mucin chemotypes. A number of bioactive microbial 
factors have been shown to induce mucin synthesis, secretion, and degradation, but few studies 
have examined the role of these in determining mucin composition [33]. There is, however, some 
evidence for the ability of certain microbial components to mediate mucin chemotypes [33, 71, 
72]. For example, administration of lipopolysaccharide (LPS) from a commensal strain of E. coli 
to germfree rats increased colonic neutral mucin [71]. In addition, LPS from H. pylori inhibited 
mucin glycosylation and sulfation when applied to rat gastric mucosal segments [72]. Whether 
the effects of the microbiota and specific microbial components on mucin chemotypes occur via 
direct recognition by intestinal goblet cells or by a microbe-induced inflammatory response to 
which goblet cells respond remains to be determined. In addition, because there are very distinct 
interspecies differences in mucin chemotype patterns [51], it is important to keep in mind that 
changes in sialo- and sulfomucin observed in animal models may not translate exactly to 
humans. For example, differences in sialomucin and sulfomucin patterns between normal rodents 
and humans are shown in Figure 1.2.  
Similar to microbial components, a number of host inflammatory signals have been 
demonstrated to alter mucin synthesis and secretion, but only a few studies have examined 
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effects on mucin composition [33]. TNFα, IL-1β, and IL-6, which are all proinflammatory 
cytokines considered to be involved in the pathogenesis of CD [73], were found to induce the 
release of less glycosylated mucins with altered carbohydrate composition from the mucin 
secreting intestinal cancer cell line LS180 [69]. In another study, TNFα increased the expression 
of α-2,3-sialyltransferase expression in HT29 cells [74], a finding that could possibly explain the 
increased sialomucin seen in active IBD. Likewise, TNFα increased α-2,3-sialyltransferase 
expression and mucin sialylation in a human respiratory glandular cell line [75]. However, TNFα 
may also contribute to mucin sulfation as evidenced by a mouse model of salmonellosis where 
TNFα was determined to be involved in an observed increase in sulfomucins in villus goblet 
cells [66]. A study using human bronchial mucosa indicated that IL-6 and IL-8 can increase 
expression of sialyltransferases and sulfotransferases, paralleling an increase in sialyl-Lewisx and 
6-sulfo-sialyl-Lewisx epitopes on bronchial proteins, including MUC4 [67]. Thus, 
proinflammatory cytokines, especially TNFα, may have an important role in mucin glycosyation, 
sulfation, and sialylation that remains to be fully understood. 
 Increased sialomucins and sulfomucins, altered terminal sugar chains, and increased gene 
expression of sulfotransferases have been observed in rodent models of intestinal nematode 
infections [76-78]. While the Th2 cytokines, IL-4 and IL-13, are considered to be mucogenic 
cytokines and important mediators of a number of other goblet cell responses to intestinal 
nematode infections, little is known regarding the ability of these cytokines to alter mucin 
composition in the human colon [79, 80]. IL-4 treatment of the human goblet-cell like line, 
LS174T, resulted in enhanced gene expression of specific N–acetylgalactosaminyltransferases 
and attached more N-acetylgalactosamine into a tandem repeat domain of the MUC2 [81]. In the 
rat intestinal epithelial cell line, IEC-6, both IL-4 and IL-13 increased gene expression of 
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sialyltransferase 4C (ST3GalIV), considered to be the major sialyltransferase expressed in the 
intestine following nematode infection [82]. Therefore, there is some indication that IL-4 and IL-
13 may be able to alter mucin composition via effects on specific glycosyltransferases, 
sulfotransferases, and sialyltranferases involved in mucin biosynthesis.  
 
TFF3 and RELMβ 
Rapid repair of mucosal epithelial damage is critical to the maintenance of epithelial 
barrier function and the prevention of prolonged inflammation. Trefoil factors (TFFs) are a 
family of small, cysteine-rich mucin-associated peptides secreted by mucus-producing cells that 
are involved in the protection and healing of mucosal epithelium [83]. The name of the family 
refers to the presence of one or more trefoil domains, which have a characteristic three-looped 
structure stabilized by three disulfide bonds formed by 6 conserved cysteine residues. Of the 
three members that have been characterized in this family, only TFF2 contains two trefoil 
domains whereas TFF1 and TFF3 contain a single domain. However, both TFF1 and TFF3 
contain a seventh cysteine, which allows for the formation of homodimers. The human trefoil 
genes are clustered on chromosome 21 at 21q22.3 in a head to tail manner [84].  
 Trefoil factors have region-specific expression within the gastrointestinal tract and have 
been shown to co-localize with mucins, suggesting an interaction between mucin and trefoil 
factors in gut protection. TFF1 is expressed in superficial cells in the fundus and antrum of the 
stomach and co-localizes specifically with MUC5AC. Direct interaction between TFF1 and 
MUC5AC has been demonstrated. TFF2 is expressed in the foveolar pits in the antrum of the 
stomach and duodenal Brunner’s glands and appears to co-localize with MUC6. TFF3 is 
expressed almost exclusively by goblet cells throughout the small and large intestine and co-
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localizes specifically with MUC2 [85]. In situ hybridization performed in the small intestine 
demonstrated hTFF3 localization within goblet cell theca and in the mucus layers. The greatest 
expression of TFF3 appears in the distal portions of the ileum and colon [86].  
TFF3 has been reported to be involved in a number of important biological functions, 
including protection of intestinal epithelium, promotion of wound healing, and promotion of 
epithelial cell migration. It has been shown to protect the mucosa from injury by noxious agents 
in vivo [79, 87, 88] and stimulate epithelial cell migration and restitution after monolayer 
wounding in vitro [89]. Targeted disruption of the TFF3 gene in mice was associated with 
increased susceptibility to dextran sodium sulfate (DSS)-induced colitis, which could be healed 
by luminal repletion of TFF3. TFF3 was also shown in vitro to be important to intestinal barrier 
function by decreasing paracellular transport through effects on claudin expression [90]. 
RELMβ belongs to the family of resistin like molecules/found in inflammatory zone 
(RELM/FIZZ). The RELMs are a family of secreted peptides, which share unique cysteine-rich 
C termini homologous to that found in the adipocyte hormone resistin. Three RELMs, excluding 
resistin, have been discovered to date: RELMα, RELMβ, and RELMγ. Of the identified RELMs, 
only RELMγ has not been described in humans. The RELM protein has three principal domains: 
(i) an N-terminal signal sequence, (ii) a variable middle portion, and (iii) a highly conserved C-
terminal signature sequence C-X11-C-X8-C-X-C-X3-C-X10-C-X-C-X-C-X9-CC-X3–6-END. Only 
RELMβ and resistin share a conserved 11thcysteine found in the N-terminus. This extra cysteine 
appears to enable homodimer formation under non-reducing conditions by both resistin and 
RELMβ [91]. Similar to the TFF and MUC proteins, the RELMs are expressed in a region-
specific manner. RELMα is most abundant in white adipose tissue but has also been detected in 
mammary tissue, heart, lung, and tongue [92]. RELMβ expression appears to be restricted to 
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goblet cells. RELMγ has been detected in bone marrow, spleen, lung, and in peripheral blood 
granulocytes [92]. 
RELMβ mRNA and protein expression in mouse is greatest in large intestine and cecum 
with limited expression in the small intestine. Analysis by in situ hybridization revealed that 
mRELMβ mRNA expression is most abundant in the lower one-half to one-third of the colonic 
crypts, coinciding with the proliferative region of the colonic epithelium, and weakened near the 
surface of the epithelium [92, 93]. Similarly, mRELMβ mRNA expression in the small intestine 
appears to be more abundant in the crypts than in the villi [93]. In min mice, which develop 
tumors akin to humans familial adenomatous polyposis due to a mutation in the Apc gene, 
RELMβ expression was greatly increased in adjacent tumors compared to normal tissues, further 
indicating a preference for RELMβ mRNA expression in cells with an enhanced rate of 
proliferation [92]. Murine RELMβ mRNA appears to have segmental pattern expression along 
the length of the colon. In situ hybridization in mouse showed alternating contiguous segments 
(~2cm long) positive for RELMβ with comparably long segments negative for RELMβ mRNA 
[93]. The significance of this pattern is not understood. Immunohistochemical analysis of protein 
expression in the colon indicated the presence of RELMβ in goblet cells in the upper crypt and 
colonic surface epithelium. Although mRNA expression was not found in upper crypts, this can 
be explained by the migration of goblet cells expressing RELMβ mRNA in the lower crypts 
towards the surface of the colonic epithelium. Immunohistochemistry also indicated that RELMβ 
was released apically rather than basally. This was confirmed by the isolation of RELMβ (as a 
homodimer) from mouse stool and detection of RELMβ in human stool [92, 93]. 
RELMβ appears to play a role in host protection against pathogens, interaction with the 
commensal bacteria, cell proliferation, inflammation, and even insulin resistance. In a study 
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comparing conventional and germfree mice, RELMβ mRNA and protein expression were 
reduced in a segmental manner in germfree mice compared to conventional mice. 
Conventionalization of germfree mice led to strong expression of RELMβ. Differences were not 
observed in the magnitude of RELMβ expression or timing for conventionalization of germfree 
BALB/c mice compared to germfree CB17SCID mice, suggesting that bacterial RELMβ 
induction occurs independent of the adaptive immune system [94]. 
It has been suggested that RELMβ may be a novel Th2 cytokine-induced immune-
effector molecule in resistance to GI nematode infection [94]. Expression and secretion of 
RELMβ is induced by intestinal nematode infection, and RELMβ binds to components of the 
nematode chemosensory apparatus and thereby inhibits its chemotaxic function [80, 94]. Further 
analysis in mice and human goblet cell lines revealed that Th1- and Th2-associated cytokines 
may play a direct role in regulating RELMβ expression in goblet cells. More specifically, 
RELMβ mRNA expression is induced by IL-4 and IL-13 and inhibited by IFNγ [94]. 
Recent studies, which have focused on RELMβ in mouse models of IBD, support the 
immune effector role of RELMβ and suggest that RELMβ may be involved in the initiation and 
perpetuation of inflammation. Hogan et al demonstrated that RELMβ−/− mice have increased 
transepithelial permeability and are more susceptible to TNBS-induced colitis but more protected 
from DSS-induced colitis [95]. The finding that RELMβ−/− mice are more protected from DSS-
induced colitis was confirmed by McVay et al [96]. In SAMP1/Fc mice, a model of spontaneous 
ileitis sharing many features with human Crohn’s disease, RELMβ was greatly increased in the 
ileum coincident with the onset of ileal inflammation [97]. Interestingly, the induction of 
RELMβ in early inflammation appeared to be independent of microbial colonization and specific 
Th1 (TNFα and IFNγ) and Th2 (IL-4 and IL-13) cytokines, raising the possibility that induction 
21 
 
and expression of RELMβ may promote inflammation and/or mucosal injury under appropriate 
pathological circumstances. Consistent with this possibility, recombinant RELMβ is able to 
induce macrophage activation and secretion of TNFα and IL-6, cytokines previously identified as 
playing a role in the pathogenesis of CD [96]. Thus, delivery of RELMβ from the lumen to the 
lamina propria through a disrupted epithelial barrier may promote inflammation by activating 
immune cells to produce inflammatory mediators [96]. Despite these interesting findings in the 
mouse, currently published studies have not examined expression or localization of RELMβ in 
CD or UC. 
 
 
CYSTEINE AND CYSTEINE DIOXYGENASE 
 
The cysteine-rich nature of goblet cell secretory products and the requirement for sulfate 
in sulfomucin production suggests that cysteine metabolism may be of central importance for 
intestinal goblet cells. In addition, cysteine is essential for a number of other cellular products 
including other proteins, glutathione, coenzyme A, and taurine (Figure 1.3). Provision of a 
cocktail containing L-cysteine along with L-threonine, L-serine, and L-proline to DSS-treated 
mice increased Muc2-positive goblet cell numbers in the surface epithelium of ulcerated regions 
and stimulated mucin synthesis while protein turnover was unaltered [98]. L-cysteine 
supplementation alone also improved colon histology and reduced DSS-induced weight loss and 
intestinal permeability, as well as local chemokine expression and neutrophil influx in a porcine 
model of colitis [99]. However, there was no mention of effects on goblet cells or mucins. Sulfur 
amino acid deficiency in neonatal pigs reduced villus and crypt goblet cell numbers in the 
jejunum but not in the ileum or colon [100]. Thus, regional differences in cysteine utilization 
may exist for intestinal goblet cells. 
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Cysteine for the intestine is likely derived from both dietary methionine and cysteine. In 
piglets, 20% of the dietary methionine intake was found to be metabolized by the gastrointestinal 
tract and primarily converted to homocysteine and cysteine via transmethylation and trans-
sulfuration, respectively [101]. Studies in rat also indicate that the small intestine possesses the 
full set of trans-sulfuration enzymes necessary to convert methionine to cysteine [102, 103]. In 
the case of dietary cysteine, less than 100% of dietary cysteine was recovered in the portal blood 
in pig studies [104, 105], indicating cysteine utilization by the intestine.  
The first step in cysteine catabolism is the oxidation of cysteine to cysteinesulfinate via 
cysteine dioxygenase (CDO, EC 1.13.11.20) [106, 107]. Cysteinesulfinate is then further 
metabolized to yield products, including hypotaurine/taurine, pyruvate and sulfate. Rodent and 
human CDO gene expression has been reported in a number of tissues [108-112], indicating the 
importance of CDO in whole body cysteine homeostasis. However, the highest mRNA levels of 
CDO were present in the liver of rats, mice, and humans. CDO mRNA was detected in whole 
tissue homogenates of murine small intestine, but the level of expression was quite low and 
appeared to be undetected at the protein level [108]. A recently published paper, though, 
demonstrated low but detectable CDO expression at the protein level in both mouse duodenum 
and colon [113]. Published studies examining CDO expression in rat or human small intestine or 
colon at the mRNA level could not be found, although an earlier study reported that rat 
enterocytes could metabolize cysteine to cysteinesulfinate via CDO [114]. However, a recent 
report described the localization of CDO specifically to goblet cells in the rat small intestine 
[115]. To our knowledge, there have been no published descriptions of CDO localization in the 
colon. Possible reasons for CDO expression in intestinal goblet cells include a mechanism for 
regulating cysteine levels when cells are not actively synthesizing cysteine-rich secretory 
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products and production of sulfate and/or taurine. Indeed, taurine was demonstrated to localize to 
mucus granules in goblet cells in mouse intestine [116]. 
 
TAURINE 
Taurine (2-aminoethanesulfonate) is one of the most abundant free amino acids present in 
the body and was reported to be the second most abundant free amino acid in human colonic 
mucosa [117-119]. Taurine is well known for its role as a conjugation substrate for bile acids, 
helping to increase polarity and aqueous solubility [118]. Taurine also has a number of 
cytoprotective properties in various tissues, including antioxidant, anti-inflammatory, 
osmoregulatory, and membrane-stabilizing effects [117, 118]. The direct precursor of taurine, 
hypotaurine, can also serve as an antioxidant [118].  
In the intestine, recent studies have revealed taurine supplementation to be beneficial in 
rodent models of inflammatory bowel disease due to its anti-inflammatory and antioxidant 
properties. Taurine supplementation was demonstrated to ameliorate inflammatory parameters in 
trinitrobenzene sulfonic acid (TNBS)-induced inflammatory bowel disease in rats, possibly by 
decreasing inflammatory reactions, oxidative damage, and apoptosis [120, 121]. Likewise, 
taurine supplementation diminished disease severity and inflammatory response in DSS-induced 
colitis in mice [122, 123]. Use of 5-aminosalicyltaurine as a colon-specific prodrug of 5-
aminosalicylic acid (5-ASA), which is cleaved into taurine and 5-ASA in cecal contents [124], 
showed enhanced anti-inflammatory effects compared to 5-ASA alone in TNBS-induced colitis 
in rats [125], again suggesting an anti-inflammatory role for taurine in the colon. Taurine can 
react with hypochlorous acid, produced by myeloperoxidase in activated neutrophils to form 
taurine chloramines [126]. Taurine chloramine exhibits strong anti-inflammatory activity by 
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downregulating nuclear factor-κb (NF-κB) activity and proinflammatory products including 
prostaglandins, nitric oxide, and cytokines, and is considered to be the major mechanism by 
which taurine potentiates the effect of 5-ASA in TNBS-induced colitis [127-129]. In vitro studies 
using human intestinal epithelial Caco-2 cells showed that taurine could inhibit TNFα-induced 
IL-8 secretion and mRNA expression [123]. Since Caco-2 cells do not express myeloperoxidase, 
this indicates that taurine alone also has anti-inflammatory effects. Taurine is absorbed across the 
apical membrane in the intestine by two transporters, TauT and PAT1 [130]. IL-1β and TNFα 
were found to increase taurine uptake by Caco-2 cells, which was associated with an increase in 
TauT mRNA levels and affinity [131]. Thus, the current evidence indicates that taurine is 
beneficial in its effects on inflammation and that intestinal epithelial cells can increase taurine 
uptake in response to inflammatory signals. However, the ability of intestinal epithelial cells to 
synthesize taurine under normal conditions and in response to inflammation remains unknown. 
In mammals, there are two pathways for taurine synthesis (Figure 1.3). One is via the 
oxidation of cysteine to cysteinesulfinate (CSA) by CDO, followed by decarboxylation of CSA 
to hypotaurine by cysteinesulfinic acid decarboxylase (CSAD; EC4.1.1.29), and finally the 
oxidation of hypotaurine to taurine by a poorly understood mechanism [132]. The other pathway 
begins with the incorporation of cysteine into Coenzyme A (CoA), followed by the release of 
cysteamine during CoA degradation, the oxidation of cysteamine to hypotaurine by cysteamine 
dioxygenase (ADO), and finally the oxidation of hypotaurine to taurine [133]. While CDO is 
expressed in both a tissue- and cell-specific manner and is especially abundant in the liver, ADO 
expression appears to be more ubiquitous [108, 113, 133, 134]. CSAD expression tends to be 
high in tissues expressing high levels of CDO [113]. There have been no published descriptions 
of ADO expression within the small intestine or colon. CSAD was also shown to be expressed in 
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mouse colon at the protein level but was not detected in mouse duodenum [113]. The inability to 
detect CSAD in mouse duodenum, however, might have been due to the use of whole tissue 
homogenates, of which goblet cells would comprise a small portion. The observed expression of 
CDO and taurine in intestinal goblet cells suggests that goblet cells may also utilize cysteine to 
synthesize taurine. Should goblet cells be capable of synthesizing taurine this might be yet 
another means by which these cells contribute to host mucosal protection. 
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Chapter 2 
CHARACTERIZATION OF SULFOMUCIN AND SIALOMUCIN EXPRESSION AND 
THEIR RELATIONSHIP WITH SULFATE-REDUCING BACTERIA IN THE  
HEALTHY HUMAN COLON 
 
ABSTRACT 
Goblet cell mucins are important components of mucosal barrier function through their 
role in forming the mucus gel layer which serves as a medium for protection between the luminal 
contents and epithelial lining. Mucins show great structural heterogeneity, but can be broadly 
classified into neutral and acidic subtypes (chemotypes), which are classified further into 
sulfomucins or sialomucins based on the presence of terminal sulfate or sialic acid groups on the 
oligosaccharide chains. Mucin chemotypes vary regionally throughout the gastrointestinal tract, 
but normal colonic mucin tends to be highly sulfated. Quantitative data and a description of 
interindividual variation in sulfo- and sialomucin content in the human colon are lacking. It is 
important to understand both regional and interindividual variation in these two mucin 
chemotypes as differences in their expression has been observed in diseases such as 
inflammatory bowel disease and colorectal cancer. Furthermore, both regional and 
interindividual variation in sulfo- and sialomucins may influence microbial colonization. For 
example, sulfomucins may promote the colonization of sulfate reducing bacteria (SRB), which 
through sulfate respiration generate the genotoxic gas hydrogen sulfide. In this regard, a pilot 
study was conducted to better characterize sulfo- and sialomucins and their relationship to SRB 
diversity in the human colon. Paired biopsies from the right colon, left colon, and rectum were 
collected from 20 healthy subjects undergoing routine screening colonoscopies. Goblet cell 
43 
 
sulfo- and sialomucins were identified by high iron diamine and alcian blue, pH 2.5 (HID/AB) 
histochemistry, quantified, and scored in each biopsy. SRB diversity was examined with nested 
PCR-terminal restriction fragment length polymorphism (TRFLP) of the 16S rRNA gene of 
Desulfovibrio spp. and the functional gene, dissimilatory sulfite reductase (dsrA). Regional 
variation was observed in sulfomucins and sialomucins with the greatest abundance of each 
found in the rectum. Scoring along the crypt revealed this was likely due to an increase in 
sulfomucin in the lower crypt and an increase in sialomucin along the surface epithelium and 
upper crypt. Pairwise comparisons of mucin data revealed interindividual differences among 
regions with the right colon exhibiting the greatest extent of interindividual 
variation.Interindividual variation in SRB profiles was found to be greater than that in mucin 
profiles and was lowest in the right colon, indicating that interindividual variation in sulfo- and 
sialomucin chemotypes does not entirely account for interindividual variation in SRB profiles. 
Combined mucin and SRB data revealed no differences in interindividual variation among 
intestinal regions. Multivariate analysis of the mucin and SRB data revealed that samples 
clustered based on subject rather than location. Using principal component analysis it was found 
that specific terminal restriction fragments (microbial phylotypes) and sulfomucin abundance 
had the greatest influence on the formation of these clusters. These results highlight the 
importance of sampling from defined colonic regions and demonstrate that while both sulfo- and 
sialomucins differ by region, their relationship with SRB is not influenced by location in the 
colon, but rather by the host. Additional studies are necessary to further elucidate the factors that 
contribute to interindividual variation in mucin chemotypes and SRB.  
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INTRODUCTION 
The colonic mucus layer is an important interface between the host epithelium and the 
luminal contents, including the mutualistic microbiota. Mucins, which are largely responsible for 
the viscous properties of the mucus layer, consist of a peptide backbone containing alternating 
glycosylated and non-glycosylated domains [1]. The oligosaccharide chains attached to the 
peptide backbone in the glycosylated domains show great structural heterogeneity [2, 3], which 
may determine the biological and physiological properties of the mucins as well as the bacteria 
able to colonize the mucus layer [4-6]. Mucins can be broadly classified into neutral and acidic 
subtypes (chemotypes), which are classified further into sulfomucins or sialomucins based on the 
presence of terminal sulfate or sialic acid groups on the oligosaccharide chain, respectively [7]. 
These mucin chemotypes can be identified using various histochemical stains. Of particular 
interest for this study is the high iron diamine and alcian blue (HID/AB) stain, which 
distinguishes sulfomucin and sialomucin [8]. Previous studies using the HID/AB stain to 
examine the distribution of sulfomucins and sialomucin report an overall predominance of 
sulfomucin in the human colon with distinct patterns of sulfomucin and sialomucin distribution 
both regionally and along the crypt [7, 9]. However, quantitative measurements of sulfomucin 
and sialomucin have not been reported and there has been little description of the extent of 
interindividual variation in acidomucin chemotypes in healthy individuals.  
Alterations in sulfo- and sialomucin chemotypes have been observed in patients with 
inflammatory bowel disease and colorectal cancer [7, 10-13]. Specifically, a significant decrease 
in sulfomucins and an increase in sialomucins have been observed in ulcerative colitis and were 
found to correlate with disease severity [10, 12, 13]. In the case of colorectal cancer a similar 
change is seen in the transitional mucosa and in non-mucinous adenocarcinomas [3, 7]. The 
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cause and significance of these changes in mucin chemotypes in disease as well as the spatial 
variation observed in healthy individuals remain to be fully understood. 
One possible consequence of the expression of particular mucin chemotypes is selection 
for specific microbiota. Carbohydrates and terminal groups on mucin oligosaccharide chains can 
serve as binding sites as well as a potential source of nutrients for microbes. A number of 
interactions between microbes and mucins have been demonstrated in the colon and other 
mucosal regions of the body [4, 6].  Particular focus is given here to the sulfate-reducing bacteria 
(SRB), members of the normal colonic microbiota, which through sulfate respiration generate the 
gas hydrogen sulfide (H2S) [14]. Previously described commensal SRB include 
Desulfotomaculum sp., Desulfobacter sp., Desulfomonas sp., Desulfobulbus sp. and 
Desulfovibrio sp. [15-20], but Desulfovibrio spp. are believed to be the most predominant [16]. 
There is considerable evidence implicating SRB and their end product, H2S, in the pathogenesis 
of UC, including the observation of increased numbers of SRB in feces of UC patients compared 
to controls and in UC patients with active disease compared to those in remission [21, 22]. In 
addition, H2S has been shown to be a potent genotoxin [23, 24] and has been linked with chronic 
inflammatory disorders of the colon [25, 26]. Relatively little is known about the diversity and 
ecology of colonic SRB populations in the human colon, but in the mouse SRB populations were 
found to be most abundant in intestinal regions harboring the greatest density of sulfomucin-
containing goblet cells [27].  Furthermore, mouse studies suggest that sulfate for sulfate reducers 
may be derived from sulfomucins rather than exogenous sulfate [28].  
The aim of the present study was to better understand spatial and interindividual variation 
in sulfomucins and sialomucins and the relationship between acidomucin chemotypes and SRB 
in the human colon. To achieve this goal sulfomucins and sialomucins were quantified and 
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scored in human colon biopsies from right colon, left colon, and rectum. Molecular-based 
methods were used to examine the diversity of Desulfovibrio spp. 16S rRNA and the functional 
dissimilatory sulfite reductase (dsrA) gene from SRB in a matched set of biopsies. The combined 
data were subjected to multivariate analyses to elucidate possible relationships between 
acidomucin chemotypes and SRB. 
 
MATERIALS AND METHODS 
Sample Collection. All procedures were approved by the Carle Foundation Hospital and 
University of Illinois at Urbana-Champaign Institutional Review Boards. Twenty healthy 
subjects (12 women and 8 men) aged 47-64 years undergoing routine screening colonoscopy at 
Carle Foundation Hospital (Urbana, IL USA) were recruited for this study. Enrolled subjects had 
no known history of gastrointestinal disease and had not been on antibiotics for at least thirty 
days prior to sample collection. After obtaining informed consent, mucosal biopsies were 
collected during a routine screening colonoscopy from the right colon, left colon, and rectum for 
mucin histochemistry, histopathological analysis, and microbial analysis. Biopsies for microbial 
analysis were immediately frozen in liquid nitrogen and then stored at -80oC. Biopsies for mucin 
histochemistry were fixed in Bouin’s solution while biopsies for histopathological examination 
were fixed in 10% neutral buffered formalin. Fixed biopsies were sent to the Carle Clinic 
Pathology Services Laboratory (Urbana, IL USA) for processing, embedding, and sectioning. 
Demographic information including age, gender, height, weight, race, and smoking were 
collected from review of subjects’ medical charts. Subject demographic information and 
endoscopic findings are summarized in Table 2.1. 
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Mucin Histochemistry and Histopathological Analysis. To identify sialomucins and sulfomucins, 
biopsy sections were stained with high iron diamine (HID) and alcian blue (AB), pH 2.5 as 
previously described [27] and counterstained with nuclear fast red for 2 minutes. For 
histopathological analysis, sections were stained with hematoxylin and eosin and then examined 
by a board certified pathologist. 
 
Quantification of Sialomucin and Sulfomucin. Images of HID/AB stained sections were captured 
using a Zeiss Axiovert 200M Microscope and the Mosaix module in Axiovision 4.5 software. 
The Automeasure module in Axiovision 4.5 was then used to select and quantify the area of 
sialomucin and sulfomucin within goblet cells based on pixel color as shown for sulfomucin in 
Figure 2.1. For each biopsy, the area of sialomucin and sulfomucin within goblet cells was 
measured for the entire section with the exception of areas that were too damaged to distinguish 
goblet cells or the epithelium. The area of each mucin was normalized to the area of epithelium 
containing the quantified mucin. 
 
Sialomucin and Sulfomucin Scoring. Positive staining for sialomucin and sulfomucin along the 
surface epithelium, upper crypt, and lower crypt was scored according to the system described in 
Table 2.2. Scoring was performed at two independent times for each image and the two scores 
were averaged. 
 
SRB Analysis. The diversity of Desulfovibrio spp. (16S rRNA gene) and SRB (dsrA gene) were 
examined using a nested PCR-terminal restriction fragment length polymorphism (TRFLP) as 
48 
 
previously described [29]. For each microbial gene target, TRFLP analyses were performed 
using two independent restriction enzymes. HpyCh4IV and ScrfI endonucleases were used 
for the digestion of Desulfovibrio spp. 16S rRNA gene amplicons. For the analysis of dsrA 
genes, nested PCR amplicons were digested with Sau96I and BstUI endonucleases (NE Biolabs). 
Profiles obtained with two independent restriction analyses (endonucleases) were concatenated 
to form a collective data set, and the resulting output files were used in multivariate statistical 
analyses 
 
Statistical Analysis. For comparison of regional and gender differences in sulfomucin and 
sialomucin areas, % sulfomucin (sulfomucin area/[sulfomucin area+sialomucin area]), and 
mucin scoring, an ANOVA and Fisher's Protected Least Significant Difference test (FLSD test) 
were used. Interindividual variation in sulfomucin and sialomucin was assessed by performing a 
pairwise comparison using the Morisita similarity index followed by an ANOVA and FLSD test 
to compare differences in similarities. Multivariate analyses were performed using matrix 
concatenation of mucin areas, mucin scores, and SRB profiles. First, non-metric 
multidimensional scaling (NMDS) analysis was performed to ordinate samples based on 
intestinal region (R, L, Re). Multivariate cluster analysis (MCA) was then carried out to group 
samples using a similarity index of 65%. NMDS ordinations were then performed to corroborate 
the MCA clusters. Principal component analysis (PCA) and factor analysis was used to identify 
major factors contributing to NMDS-clusters formation. Because PCA ordination confirmed 
NMDS analysis, PCA-factors were overlaid on NMDS plots. Finally, multivariate ANOVA 
(MANOVA) was used for an inferential statistical analysis for the quantitative assessment of 
SRB and mucin profiles among clusters. All multivariate statistical analyses were performed 
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with the PAST software package [30-33]. ANOVA and FLSD test were carried out using SAS 
software (Statview, Version 5.0.1; SAS Institute, Cary, NC). Differences were considered 
significant at p< 0.05. 
 
RESULTS 
Mucin Histochemistry. Both spatial and interindividual variation in sulfomucin and sialomucin 
content were evident in the HID/AB stained biopsies (Figure 2.2). In general, goblet cells in the 
right colon were predominantly sulfomucin positive with a few sialomucin positive goblet cells 
near the surface epithelium and occasionally in the lower crypt. Goblet cell mucins in the left 
colon were predominantly sulfated with variable numbers of sialomucin positive goblet cells 
found in the upper crypt and surface epithelium. In the rectum, an increase in the density of 
sialomucin in the surface epithelium and upper crypt was consistently found among individuals. 
The lower crypt in the rectum primarily contained sulfomucin positive goblet cells. 
Interindividual variation included differences in the abundance of sulfomucin and sialomucin 
and their spatial distribution. 
 
Sulfomucin and Sialomucin Abundance.  To better understand regional and interindividual 
differences in sialo- and sulfomucin abundance, the area of sialo- and sulfomucin staining within 
goblet cells was measured per area of epithelium analyzed. Data obtained from quantitative 
analysis of sulfomucin and sialomucin staining in all 60 biopsies as well as the percent of stained 
mucin that stained as sulfomucin (% sulfomucin = sulfomucin area/[sulfomucin area + 
sialomucin area]) are shown in Table 2.3. These data reveal that sulfomucin containing goblet 
cells are present in all biopsies collected and that sulfomucin abundance is greater than 
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sialomucin abundance in all biopsies with the exception of the right colon biopsy from subject 4 
and the rectal biopsy from subject 8. Comparison of sulfomucin and sialomucin among the three 
colonic regions revealed both mucin chemotypes to be most abundant in the rectum, but not 
significantly different between right colon and rectum (Figure 2.3A and B). Analysis of the % 
sulfomucin revealed sulfomucins to be predominant in all three regions (Figure 2.3C), but less 
predominant in the rectum where the presence of sialomucins is increased. A comparison of 
sulfomucin and sialomucin abundance between male and female subjects revealed that female 
subjects harbored significantly more sialomucin in the rectum than male subjects (Figure 2.4), 
although the abundance of the two acidomucin chemotypes was similar in male and female 
subjects for all other colonic regions.  
 
Sulfomucin and Sialomucin Distribution along the Crypt. To define sulfomucin and sialomucin 
gradients along the crypt semi-quantitatively, sulfo- and sialomucin staining were scored along 
the surface epithelium, upper crypt, and lower crypt. These data are shown in Table 2.4.  Score 
comparisons for each region are shown in Figure 2.5. For sulfomucin, scores were highest in the 
lower crypt of the left colon and rectum and lowest for the surface epithelium of the rectum. 
Thus, the greater abundance of sulfomucin in the rectum likely reflects more sulfomucin in the 
lower crypt. A trend towards decreasing sulfomucin on the surface epithelium in more distal 
regions of the colon was also observed. Sialomucin scores were highest in the surface epithelium 
and upper crypt of the rectum, indicating that the greater area of rectal sialomucin reflects 
increasing amounts in those regions of the crypt. Both surface and upper crypt sialomucin 
appeared to increase for more distal sections. Sialomucin score was lowest in the lower crypt of 
the left colon.  
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Interindividual Variation in Sulfomucin and Sialomucin. To assess interindividual variability in 
sulfomucin and sialomucin abundance and distribution along the crypt-surface epithelium within 
the three colonic regions, pairwise similarities between right colon, left colon and rectum were 
estimated using Morisita similarity indices (Figure 2.6). Statistical analysis revealed that for 
mucin abundance (Figure 2.6A), interindividual variation was greatest in the right colon (R vs 
R) and lowest in the left colon (L vs L) with rectum (Re vs Re) being intermediate. Furthermore, 
mucin abundance was most similar between the right colon and left colon (R vs L) and least 
similar between the right colon and rectum (R vs Re). Interindividual variation in mucin scores 
was also highest in the right colon, but was comparable between the left colon and rectum 
(Figure 2.6B).  Mucin scores were most similar between right colon and left colon and left colon 
and rectum and least similar between right colon and rectum. Analysis of combined mucin area 
and mucin score data indicated that interindividual variation in overall mucin data was lowest in 
the rectum and equivalent between the right and left colon (Figure 2.6C). Similar to the score 
data alone, combined score and abundance data were most similar between right colon and left 
colon and between left colon and rectum and least similar between right colon and rectum. 
 
SRB Analysis. Nested PCR for the Desulfovibrio spp. 16S rRNA gene demonstrated that all 20 
subjects harbored mucosa-associated Desulfovibrio populations in at least one colonic region. 
Examination of SRB populations associated with the colonic mucosa via nested PCR analysis of 
a functional gene for sulfate reduction, dissimilatory sulfite reductase (dsrA) indicated that 19 out 
of 20 subjects harbored mucosa-associated SRB populations in at least one region of the colon. 
Neither the Desulfovibrio spp. 16S rRNA gene nor the dsrA gene was detected in the right colon 
of subject 6 and the left colon biopsy of subject 1. Consequently, these samples were excluded 
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from further analyses of interindividual variation and multivariate analyses involving SRB 
profiles. It should be noted that histopathological analysis of additional biopsies from left colon 
of subject 1 showed acute inflammation and minor abnormalities were observed in additional 
biopsies from right colon of subject 6. To measure diversity of mucosa associated SRB in the 
human colon, TRFLP analyses of the Desulfovibrio 16S rRNA gene and the dsrA functional 
gene were conducted. Multivariate analysis of the resulting SRB profiles for each biopsy 
revealed that SRB are highly diverse within healthy subjects, but the diversity of SRB is 
comparable across colonic regions. However, in a few samples, SRB profiles were found to be 
slightly more homogenous in the right colon than other regions. For additional details and figures 
see reference [29].   
 
Interindividual Variation in SRB Profiles and Combined SRB and Mucin Profiles. Interindividual 
variation in SRB profiles was analyzed by performing pairwise comparisons among right colon, 
left colon and rectum using Morisita similarity indices (Figure 2.7A). Statistical analysis 
indicated that interindividual variation was greater in the rectum than the right colon, but neither 
differed significantly from the left colon, and left colon and rectum exhibited the greatest 
difference in SRB profiles. Furthermore, the much lower similarity indices for SRB profiles 
compared to mucin abundance and scores (Figure 2.6), indicate greater interindividual variation 
in SRB profiles than in mucin chemotypes. Interindividual variation was also examined in 
combined SRB profile and mucin data and found to be comparable in all three regions (Figure 
2.7B). The low similarity indices demonstrate high interindividual variation in combined SRB 
and mucin data. 
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Multivariate Cluster Analysis of Mucin and SRB Data. Multivariate cluster analysis of 
sulfomucin and sialomucin areas demonstrated clustering by region and minimal clustering by 
subject (Figure 2.8). Rectal biopsies tended to cluster, while right colon and left colon biopsies 
were often found in a common cluster. Similar observations were made for cluster analysis of 
mucin scoring data (Figure 2.9) as well as cluster analysis of combined mucin areas and scoring 
data (Figure 2.10). Thus, for sulfo- and sialomucins there was generally more similarity among 
the same regions from different subjects than different regions from the same subject.   
On the other hand, cluster analysis for SRB profiles showed clustering by subject with 
minimal clustering by region (Figure 2.11), indicating that microbial profiles tended to be more 
similar within the same individual than from the same region of different individuals. Due to the 
high interindividual variation, MCA of combined SRB and mucin profiles (Figure 2.12) was 
performed and a similarity index of 65% was used to select samples with comparable SRB-
mucin profiles. This approach revealed the presence of four distinct SRB-mucin clusters, which 
encompassed all but five samples. Additionally, the SRB-mucin profiles clustered by subject 
rather than by colonic region. However, within some clusters of subjects, greater similarity 
indices could be found between samples from the same region. For example, all biopsies from 
subject 7 and 8 were contained in cluster III, but right colon from subject 7 (7R) was more 
similar to right colon of subject 8 (8R) than to the left colon of subject 7 (7L). Intriguingly, 3 of 
the 5 samples that did not fit within the four main clusters were identified as having minor 
abnormalities by routine histopathological analysis. 
 
Non-Metric Multidimensional Scaling and Principal Component Analysis of SRB-Mucin 
Profiles.  NMDS was performed for SRB-mucin profiles using the Morisita similarity index with 
54 
 
individual samples identified by region. As shown in Figure 2.13, the results of the NMDS 
analysis corroborated results from MCA in that samples did not cluster by location, but appeared 
to cluster by subject. A MANOVA was performed to compare SRB-mucin profiles among 
colonic regions and confirmed that SRB-mucin profiles were similar among right colon, left 
colon, and rectum.  Because determination of clusters in the original NMDS plot appeared 
somewhat ambiguous, MCA was then carried out in order to group samples using a similarity 
index of 65% and then NMDS ordinations were performed to corroborate the MCA clusters. 
These analyses also revealed four distinct clusters (Figure 2.14). MANOVA confirmed SRB and 
mucin profiles diverge significantly among these four clusters. To identify major factors 
contributing to NMDS-clusters formation, PCA and factor analysis were performed. These 
analyses revealed 13 major factors contributing to the NMDS ordination. These factors were 
retrieved from the concatenated data matrix and included in a heat map. This figure shows the 
relative abundance of the terminal fragments identified as most contributory by PCA and all 
mucin data for each sample in the clusters and the cluster outliers to determine how these factors 
might influence formation of the different clusters (Figure 2.15). For certain terminal fragments, 
obvious differences in relative abundance among clusters (e.g. the relative abundance of terminal 
fragment 3 is higher in cluster I samples than all other samples) were evident, while the influence 
of specific terminal fragments and particular attributes of the mucin data was less obvious for 
other clusters.  
 
DISCUSSION 
In the present study a quantitative analysis of goblet cell sulfomucins and sialomucins in 
human colon biopsies was performed and compared with an analysis of SRB profiles from 
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matched biopsies collected from the same colonic regions among the individuals. Analysis of the 
two mucin chemotypes revealed both spatial and interindividual variation. Spatial variation in 
acidomucin profiles has been described previously, but had not been examined quantitatively.  
Quantification of the area of goblet cell mucin staining per area of epithelium (mucin abundance) 
revealed that sulfomucin and sialomucin were most abundant in the rectum. Sulfomucin was the 
predominant mucin chemotype in all three regions. The increase in sialomucins in the rectum 
compared to the right colon and an overall predominance of sulfomucin in the human colon is in 
accord with previously described observations [7].  Sulfomucin may offer additional protection 
from luminal insults by increasing mucus viscosity and resistance to bacterial degradation and 
microbe adhesion [5]. Thus, individuals who have either a lower predominance of sulfomucin or 
lower abundance of sulfomucin may be at greater risk to the effects of luminal substances with 
the potential to cause disease. Of interest, two out of the sixty biopsies did not show a 
predominance of sulfomucin.  Additional studies should be conducted to determine whether 
individuals with lower sulfomucin predominance or overall sulfomucin abundance are at higher 
risk for developing gastrointestinal disease. Providing quantitative data for sulfomucin and 
sialomucin abundance should enhance the study of mucin chemotypes in disease by allowing 
definition of a normal range for each mucin chemotype. Furthermore, these data point out the 
importance of sampling from defined regions in experimental investigations of the human colon. 
Intriguingly, a significant increase was observed for sialomucin abundance in the recturm 
of female subjects. Sulfomucin abundance, on the other hand, was similar in the three colonic 
regions between male and female subjects. The greater abundance of sialomucin in the female 
rectum could possibly reflect hormonal regulation of rectal sialomucin production as colonic 
sialomucin was previously found to increase during the late progesterone phase of the menstrual 
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cycle [34].  The observed gender difference in rectal sialomucin, however, should be examined 
further in a larger cohort of subjects to determine the consistency of this observation. A larger 
study would also be useful in determining whether other demographic factors such as smoking, 
age, race, or ethnicity affect mucin chemotypes, which could not be adequately assessed in this 
study due to the small sample size.  
 Scoring of each mucin chemotype along the surface epithelium, upper crypt, and lower 
crypt was performed to provide a semi-quantitative measurement of mucin variation along the 
crypt. Areas were not measured in this case due to the time consuming nature of the area 
analysis.  Scoring confirmed previous descriptions of mucin chemotype distributions along the 
crypt, including a greater number of sialomucin containing goblet cells in the upper crypt of the 
rectum [7]. The scoring analysis also allowed us to determine that the increase in sulfomucin 
abundance measured in the rectum compared to right colon was due to increased sulfomucin in 
the lower crypt rather than in the upper crypt or surface epithelium. Such information is useful as 
it may be that mucins in surface and upper crypt goblet cells are more important in mediating 
host microbe interactions. On the other hand, disease related changes in mucin chemotypes may 
initially be observed in the lower crypt with less differentiated goblet cells and then be 
perpetuated as cells migrate up the crypt.  
 Interindividual variation in sulfo- and sialomucin abundance and distribution along the 
crypt among right colon, left colon, and rectum was measured quantitatively in the present study. 
Interindividual variation in O-acetylation of mucin sialic acid was previously reported in the 
colon [35], but to our knowledge other studies have not been reported that provide a detailed 
analysis of interindividual variation in sulfo- and sialomucins within specific colonic regions of 
healthy individuals.  The greatest heterogeneity in both sialo- and sulfomucin abundance and 
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distribution along the crypt was found in the right colon, while left colon was most homogenous 
in terms of abundance, and rectum was most homogenous in terms of distribution along the crypt 
as well as overall mucin data. Thus, when comparing these mucin chemotypes between diseased 
and normal tissue, it may be easier to find differences in the rectum where there is less variation 
among normal individuals. This observation may also be relevant to reports of altered mucin 
sulfation and sialylation in ulcerative colitis, which shows ascending involvement of the colon 
from rectum, than in Crohn’s disease which can involve any region of the gastrointestinal tract 
[36].  
While quantitative analysis of sulfo- and sialomucin abundance and distribution along the 
crypt revealed spatial and interindividual variation in these two mucin chemotypes, the factors 
that contribute to this variation remain to be defined. It is likely that both environmental and 
genetic components are involved. Previously reported heterogeneity in O-acetylation of 
sialomucin is believed to reflect genetic differences in expression of an O-acetyltransferase [37]. 
Thus, there may be some differences in specific sulfo- and/or sialotransferases involved in 
determination of sulfo- and sialomucin expression. Animal studies indicate that the commensal 
microbiota and diet may also influence mucin composition [6, 38-42], but additional studies are 
needed to understand their contribution in humans.  
Nested PCR for the Desulfovibrio spp. 16S rRNA gene demonstrated that all 20 subjects 
harbored mucosa-associated Desulfovibrio populations in at least one colonic region and, for 
dsrA, that 19 out of 20 subjects harbored mucosa-associated SRB populations in at least one 
region of the colon [29]. These results indicate that SRB populations are ubiquitously associated 
with the human colonic mucosa and concur with observations by Fite et al [43], in which the use 
of quantitative PCR also revealed that intestinal mucosa is persistently colonized by 
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Desulfovibrio spp.  TRFLP analysis further indicated that mucosa-associated SRB populations 
are highly diverse in the human colon [29]. Additional analyses of microbial diversity revealed 
that the right colon, left colon and rectum harbor similar SRB populations [29].  In contrast to the 
mucin data, interindividual variation in SRB profiles showed increasing heterogeneity moving 
proximally to distally from the right colon to the rectum. Variability among subjects and regions 
was much greater for SRB profiles than mucin data, indicating that additional factors are 
contributing to SRB heterogeneity. However, combined SRB-mucin profiles showed similar 
variability across the colon.   
 Multivariate cluster analysis revealed that sulfo- and sialomucin abundance and 
distribution along the crypt was more similar among the same regions from different subjects 
than for different regions from the same subject, while SRB profiles were generally more similar 
within the same individual than from the same region of different individuals. Thus, the observed 
regional differences in sulfo- and sialomucins do not appear to significantly impact regional 
differences in SRB profiles.  
 Multivariate analyses of SRB-mucin profiles revealed the presence of four distinct 
profiles in this particular cohort of healthy human subjects. In addition, it demonstrated that the 
relationship between SRB diversity and sulfo- and sialomucins appeared to be influenced to a 
greater extent by undetermined host-specific attributes than colonic location. Specific terminal 
fragments and sulfomucin abundance were identified by PCA to be the major factors 
contributing to the formation of the four clusters. This indicates that in some healthy individuals, 
sulfomucin concentrations may influence the diversity of SRB. However, in other subjects 
sulfomucin abundance was not observed to significantly influence SRB profiles. Of note, 3 of the 
5 samples that did fit into the four groups were sampled from regions that were identified as 
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having some abnormality by histopathological analysis.  This suggests that abnormalities in 
colon tissue may lead to altered SRB-mucin profiles, which prevent these samples from 
clustering with one of the four “healthy” groups or perhaps results in the formation of a separate 
cluster. Examination of SRB-mucin profiles in additional colon biopsies from normal and 
diseased tissue will be needed to distinguish these possibilities.  
In summary, this study provides the first quantitative assessment of regional and 
interindividual variation in sulfo- and sialomucins in healthy human subjects. In addition, it 
provides the first description of the relationship between SRB and specific acidomucin 
chemotypes. Four distinct mucin-SRB profiles were observed in the human colon for this 
particular cohort of healthy subjects. Furthermore, the mucin-SRB profiles were host-specific in 
healthy individuals. This outcome indicates that it may be possible to detect distinct SRB-
acidomucin profiles in subjects susceptible to or exhibiting chronic colonic disease. 
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Table 2.3: Sulfomucin and sialomucin areas and % sulfomucin for each biopsy. 
Subject #  Region 
Sulfomucin Area 
(µm2/100µm2 
epithelium) 
Sialomucin Area 
(µm2/100µm2 
epithelium) 
% 
Sulfomucin 
1 Right 12.56 0.46 96.50 
1 Left 11.11 1.42 88.64 
1 Rectum 17.88 16.41 52.14 
2 Right 13.22 2.61 83.49 
2 Left 16.39 0.51 96.98 
2 Rectum 23.61 11.73 66.80 
3 Right 16.17 0.25 98.46 
3 Left 14.61 0.05 99.67 
3 Rectum 26.01 7.60 77.39 
4 Right 5.48 6.13 47.18 
4 Left 11.79 3.61 76.55 
4 Rectum 71.07 21.00 77.19 
5 Right 23.23 0.03 99.85 
5 Left 80.70 5.40 93.73 
5 Rectum 39.74 17.52 69.41 
6 Right 24.54 0.14 99.45 
6 Left 18.67 1.00 94.91 
6 Rectum 22.35 6.62 77.15 
7 Right 26.31 0.03 99.87 
7 Left 36.72 7.64 82.78 
7 Rectum 33.57 4.61 87.93 
8 Right 40.07 0.64 98.43 
8 Left 29.13 3.67 88.81 
8 Rectum 24.47 28.54 46.16 
9 Right 3.70 2.23 62.37 
9 Left 7.83 1.51 83.80 
9 Rectum 10.75 3.13 77.43 
10 Right 6.88 0.19 97.34 
10 Left 10.08 0.67 93.76 
10 Rectum 23.24 5.73 80.21 
11 Right 16.68 1.15 93.57 
11 Left 81.91 8.86 90.24 
11 Rectum 30.39 8.56 78.03 
12 Right 8.03 4.87 62.23 
12 Left 17.16 0.83 95.41 
12 Rectum 36.46 5.96 85.95 
13 Right 15.29 0.65 95.90 
13 Left 34.02 3.24 91.29 
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Tab1e 2.3 (cont.) 
13 Rectum 15.10 7.33 67.32 
14 Right 19.06 0.15 99.20 
14 Left 22.40 2.40 90.33 
14 Rectum 17.29 4.40 79.72 
15 Right 6.10 3.74 61.98 
15 Left 14.02 3.06 82.08 
15 Rectum 24.37 14.10 63.35 
16 Right 19.37 0.74 96.34 
16 Left 16.87 0.88 95.06 
16 Rectum 29.85 5.04 85.56 
17 Right 15.27 0.18 98.82 
17 Left 18.50 1.13 94.23 
17 Rectum 36.03 8.72 80.52 
18 Right 13.51 0.13 99.06 
18 Left 20.19 0.92 95.63 
18 Rectum 23.95 0.81 96.73 
19 Right 35.96 0.00 100.00 
19 Left 23.00 0.01 99.96 
19 Rectum 23.67 0.12 99.51 
20 Right 5.37 0.00 99.98 
20 Left 7.20 0.03 99.64 
20 Rectum 9.50 0.47 95.31 
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      Table 2.4: Sulfomucin and sialomucin scores along the crypt and surface epithelium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Subject # Region Sulfomucin Score Sialomucin Score Surface Upper Lower Surface Upper Lower 
1 Right 2 2 2 1 1 1 
1 Left 2.5 2 2 2.5 2 0.5 
1 Rectum 1 2 2 3 2.5 2 
2 Right 2 2 1 0 1 3 
2 Left 2.5 2.5 2.5 1.5 1 0.5 
2 Rectum 1 2.5 3 3 2.5 1 
3 Right 2.5 2 2 1 1 0 
3 Left 2.5 2 2 1 1 0 
3 Rectum 2 2.5 3 2.5 2.5 0.5 
4 Right 2 1.5 1 2 2.5 3 
4 Left 1 1.5 1.5 1 1 2 
4 Rectum 1 1.5 2 3 1.5 1 
5 Right 3 3 2.5 1 1 1 
5 Left 2.5 3 3 3 2 1 
5 Rectum 1 1 3 3 3 1 
6 Right 1.5 2 2 1 1 0 
6 Left 1 2 2.5 1 1.5 0.5 
6 Rectum 1 1 2 2 3 1.5 
7 Right 1 2.5 2 1 1 1 
7 Left 1 2.5 2.5 2.5 2 1 
7 Rectum 1 2 2.5 1.5 2.5 1 
8 Right 1 2 2.5 1 1 1 
8 Left 1 2.5 2.5 2.5 2.5 1 
8 Rectum 1 1.5 2.5 3 3 1 
9 Right 3 2.5 2 1 2 2.5 
9 Left 2.5 2.5 3 1.5 1 1 
9 Rectum 1.5 2 3 3 3 2 
10 Right 2 2 2 1 1 0.5 
10 Left 1.5 2 3 1.5 2.5 1 
10 Rectum 1 2 3 2.5 3 1 
11 Right 1 1 2 1 1.5 1 
11 Left 1 1.5 1.5 1 1.5 1 
11 Rectum 1 1.5 2 1.5 2 1 
12 Right 3 1.5 1 1 1 3 
12 Left 1 2 3 1.5 1 0 
12 Rectum 1 2 3 1.5 3 1 
13 Right 1.5 2 2 1 1 1.5 
13 Left 1 2 2.5 1 1 1 
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    Table 2.4 (cont.) 
 13 Rectum 1 1 2.5 2.5 3 1.5 
14 Right 3 2.5 2 1 0.5 0 
14 Left 2 3 3 2 2.5 1 
14 Rectum 1 2 3 2 2.5 1 
15 Right 2 1 1 2 2 3 
15 Left 1.5 2.5 2 2.5 1.5 1 
15 Rectum 1 2 3 3 3 1.5 
16 Right 3 3 3 1 0.5 0 
16 Left 3 3 3 1 1 0 
16 Rectum 2 3 3 2.5 1.5 1 
17 Right 2.5 2 2.5 1 1 0.5 
17 Left 2 3 3 2 1 0.5 
17 Rectum 1 2.5 3 2.5 3 1 
18 Right 2 2 2 1 1 1 
18 Left 2 3 3 1 1 0 
18 Rectum 1 3 3 1 1.5 1 
19 Right 3 3 3 1 1 0 
19 Left 3 3 3 1 0 0 
19 Rectum 3 2.5 2 0 1 1 
20 Right 2 2 2 1 0 0 
20 Left 2 3 3 1.5 1 0.5 
20 Rectum 1 3 3 1 2 1 
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Chapter 3 
THE EFFECT OF MICROBIAL AND HOST INFLAMMATORY SIGNALS ON  
MUCIN SULFATION 
 
ABSTRACT 
The signals that mediate goblet cell expression of specific mucin chemotypes are poorly 
defined. Both animal and in vitro studies show that mucin chemotype may be altered by changes 
in the normal microbiota and inflammation.
 
To begin to identify factors that may elicit this 
response, human adenocarcinoma-derived LS174T cells, which have a goblet cell-like phenotype 
and produce both sulfo- and sialomucins, were used to examine the effects of selected host and 
microbial factors on mucin sulfation. Expression of genes encoding goblet cell secretory 
products mucin 2 (MUC2), resistin-like molecule β (RETNLB), and trefoil factor 3 (TFF3) and 
Golgi sulfotransfereases, carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 (CHST5) 
and galactose-3-O-sulfotransferase 2 (GAL3ST2), were determined by quantitative RT-PCR 
following treatment with bacterial flagellin, TNFα, or the mucogenic cytokine IL-13. Expression 
of caudal type homeobox 2 (CDX2) and toll-like receptor 5 (TLR5) genes were also analyzed. 
Sulfomucin expression was examined via HID/AB staining and immunofluorescent staining for 
the Sulfo Lea antigen, which is synthesized in part by GAL3ST2. Flagellin, IL-13, and TNFα 
were all found to significantly increase GAL3ST2, MUC2, TFF3, and TLR5 expression, but only 
IL-13 and TNFα increased CHST5 expression and decreased RETNLB expression. Only IL-13 
increased CDX2 expression. Mucin sulfation based on HID/AB staining was significantly 
increased in response to both flagellin and IL-13, but not TNFα. Only treatment with flagellin 
increased the expression of the Sulfo Lea antigen. These results indicate that flagellin, IL-13, and 
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TNFα have differential effects on mucin sulfotransferases and sulfation as well as the goblet cell 
secretory product genes. IL-13 may increase sulfomucins primarily via increased expression of 
CHST5, while flagellin may increase sulfomucins by increasing expression of GAL3ST2. 
Although TNFα increased expression of both sulfotransferase genes, it did not increase 
sulfomucin content during the time period examined. Together these data indicate that both host 
and microbial factors influence mucin chemotypes.  
 
INTRODUCTION 
Inflammatory bowel disease (IBD) is a complex disorder characterized by poorly 
controlled chronic inflammation of the intestinal mucosa [1]. A number of changes in mucins 
and goblet cells have been reported in association with IBD. These include alterations in the 
thickness of the mucus gel layer, goblet cell number and intracellular mucin content, and mucin 
glycosylation [2-5]. Although decreased sulfation of mucins has been associated with active 
inflammation in human IBD, the underlying causes and the relationship to disease pathology 
remain undefined. There is a similar lack of understanding about the factors governing both 
regional and interindividual variation observed in sialo- and sulfomucin chemotypes in healthy 
individuals (described in Chapter 2). 
Both animal and in vitro studies demonstrate that mucin chemotype may be altered by 
changes in the normal microbiota and inflammation [6-10]. The evidence for microbial 
modulation of mucin chemotypes comes from developmental studies and studies comparing 
conventionally raised and germfree rodents. In mice, for example, the temporal development of 
sialo- and sulfomucin chemotypes in the colon appears to parallel the establishment of microbial 
communities and is not observed in germfree mice, in which crypt mucins remain predominantly 
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sulfated [7, 11]. Specific microbial components or products may be responsible for the observed 
effects of microbiota on mucin chemotypes.  
A number of bioactive microbial factors have been shown to induce mucin synthesis, 
secretion, and degradation, but few studies have examined the role of these in determining mucin 
composition [7]. There is, however, some evidence for the ability of certain microbial 
components to alter mucin chemotypes [7, 12, 13]. For example, administration of 
lipopolysaccharide (LPS) from a commensal strain of E. coli to germfree rats increased colonic 
neutral mucin [12]. In addition, LPS from H. pylori inhibited mucin glycosylation and sulfation 
when applied to rat gastric mucosal segments [13]. Whether the effects of the microbiota and 
specific microbial components on mucin chemotypes occur via direct recognition by intestinal 
goblet cells or by a microbe-induced inflammatory response to which goblet cells respond 
remains to be determined. In addition, because of distinct interspecies differences in mucin 
chemotype patterns [14], it is important to bear in mind that changes in sialo- and sulfomucin 
observed in animal models may not translate to humans. 
Similar to microbial components, a number of host inflammatory signals alter mucin 
synthesis and secretion, but only a few studies have examined effects on mucin composition [7]. 
TNFα, IL-1β, and IL-6, which are all proinflammatory cytokines considered to be involved in the 
pathogenesis of CD [1], were found to induce the release of less glycosylated mucins with 
altered carbohydrate composition from the mucin-secreting intestinal cancer cell line LS180 
[10]. In another study, TNFα increased the expression of α-2,3-sialyltransferase expression in 
HT29 cells [15], a finding that is consistent with the increased sialomucin seen in active IBD. 
Likewise, TNFα increased α-2,3-sialyltransferase expression and mucin sialylation in a human 
respiratory glandular cell line [16]. However, TNFα may also contribute to mucin sulfation as 
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evidenced by a mouse model of salmonellosis where TNFα was linked to an observed increase in 
sulfomucins in villus goblet cells [6]. A study using human bronchial mucosa indicated that IL-6 
and IL-8 can increase expression of sialyltransferases and sulfotransferases, paralleling an 
increase in sialyl-Lewisx and 6-sulfo-sialyl-Lewisx epitopes on bronchial proteins, including 
MUC4 [8]. Thus, proinflammatory cytokines, especially TNFα, may have an important role in 
mucin glycosyation, sulfation, and sialylation that remains to be fully understood. 
 Increased sialomucins and sulfomucins, altered terminal sugar chains, and increased gene 
expression of sulfotransferases have been observed in rodent models of intestinal nematode 
infections [17-19]. While the Th2 cytokines, IL-4 and IL-13, are considered to be mucogenic and 
important mediators of a number of other goblet cell responses to intestinal nematode infections, 
little is known regarding the ability of these cytokines to alter mucin composition in the human 
colon [20, 21]. IL-4 treatment of the human goblet-cell like line, LS174T, resulted in enhanced 
gene expression of specific N–acetylgalactosaminyltransferases and stimulated the attachment of 
more N-acetylgalactosamine into a tandem repeat domain of the MUC2 [22]. In the rat intestinal 
epithelial cell line, IEC-6, both IL-4 and IL-13 increased gene expression of sialyltransferase 4C 
(ST3GalIV), considered to be the major sialyltransferase expressed in the intestine following 
nematode infection [23]. Therefore, there is some indication that IL-4 and IL-13 may alter mucin 
composition via effects on specific glycosyltransferases, sulfotransferases, and sialyltransferases 
involved in mucin biosynthesis.  
Mucin sulfation occurs within the trans-Golgi as a late step in glycoprotein synthesis 
when specific sulfotransferases transfer sulfate from 3′ -phosphoadenosine 5′ -phosphosulfate 
(PAPS) to mucin O-glycans at the C-3 position of galactose residues or the C-6 position of N-
acetylglucosamine [24, 25]. Of the known galactose 3-O-sulfotransferases and N-
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acetylglucosamine-6-O sulfotransferases, galactose-3-O-sulfotransferase 2 (GAL3ST2) appears 
to be the sulfotransferase responsible for sulfate addition to the C-3 position of Gal in human 
colonic mucins and carbohydrate (N-acetylglucosamine 6-O) sulfotransferase 5 (CHST5) the 
most likely candidate for sulfation of the C-6 position of N-acetylglucosamine [26-28].  Evidence 
for the involvement of these two sulfotransferases in colonic sulfomucin synthesis includes the 
downregulation of GAL3ST2 expression in non-mucinous adenocarcinomas, corresponding to a 
decrease in sulfomucin expression [26], and the abundance and specificity of CHST5 for human 
small intestine and colon [27, 28]. In addition, CHST5 shows a preference for sulfating O-linked 
chains of the mucin-type [27], suggesting that it is involved in transfer of sulfate to the C-6 
position of N- acetylglucosamine in sulfomucins.  
 The aim of this study was to better understand both host and microbial factors that 
contribute to intestinal goblet cell mucin sulfation by examining effects of bacterial flagellin, IL-
13, and TNFα on sulfotransferases, CHST5 and GAL3ST2, and sulfomucin production in 
intestinal goblet cells. The human colonic LS174T adenocarcinoma cell line, which has a goblet 
cell-like phenotype, was used for this purpose [29]. This cell line synthesizes and constitutively 
secretes mucins as well as other goblet cell products and is responsive to conventional mucin 
secretagogues [30, 31]. Furthermore, unlike many other mucin-producing cell lines, the LS174T 
cell line produces both sialo- and sulfomucin under normal growth conditions [7, 30].  
 
MATERIALS AND METHODS 
Reagents and Cell Culture. Recombinant human IL-13 and TNFα were purchased from 
PeproTech. Recombinant Flagellin from S. typhimurium was purchased from InvivoGen. The 
human LS174T colorectal cancer cell line was obtained from the American Type Culture 
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Collection (ATCC). LS174T cells were maintained in Minimum Essential Medium (MEM) 
supplemented with 10% Fetalplex (Gemini Biosciences), 1.5 g/L of Na2CO3, 50 units/mL 
penicillin G and 50 mg/mL streptomycin sulfate at 37°C in 5% CO2.  
 
Treatments for Gene Expression and IL-8 Secretion. Cells were seeded into 24-well plates at a 
density of 2 x 105 cells/well and allowed to grow for 48 h. Cells were then washed twice with 1X 
HBSS and fresh antibiotic-free media containing different concentrations of flagellin, IL-13, or 
TNFα were added to the cells. After 24 h, conditioned media were collected for measurement of 
IL-8 secretion, and cells were harvested for RNA isolation. 
 
RNA Isolation and Reverse Transcription. Total RNA was isolated from cells using the RNeasy 
Plus Kit (Qiagen) according to the manufacturer’s instructions for animal cells. The quality and 
quantity of RNA isolates were determined by Nanodrop (Thermo Fisher Scientific). RNA 
isolates were reverse transcribed using the High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) or Superscript III First Strand Synthesis system (Invitrogen). 
 
 
TLR Expression. Gene expression for human TLRs 1-10 was examined in LS174T cells using 
conventional RT-PCR as previously described [32], except 400 ng of LS174T cell cDNA or 
equivalent of no reverse transcription control was used in each 25 uL PCR reaction, and cycles 
were extended to 40. 
 
 
Gene Expression. Quantitative real-time PCR was performed using SYBR Green PCR Master 
Mix (Applied Biosystems) and the primers described in Table 3.1. Reactions were run in 
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triplicate in a 384-well plate using an Applied Biosystems 7900HT Fast Real-Time PCR System. 
Final quantifications were performed using the standard curve method with the geometric mean 
of GAPDH and RPLP0 used for normalization. No reverse transcription reactions were 
performed to confirm the specificity of the reactions for RNA.  
 
IL-8 Secretion. Secretion of IL-8 from LS174T cells was measured in conditioned media using a 
Human CXCL8/IL-8 Quantikine ELISA Kit (R & D Systems) according to the manufacturer’s 
instructions.  
 
Sulfomucin Analysis via High Iron Diamine and Alcian Blue (HID/AB) Staining. LS174T cells 
were seeded in µ-chamber 12-well slides (IBIDI) at a density of 4 x 104 cells/well and allowed to 
grow for 48 h. Cells were then washed twice with 1X HBSS, and fresh antibiotic-free media 
containing different concentrations of flagellin, IL-13, or TNFα were added to the cells. After 48 
h, cells were washed once with 1X PBS and fixed in Carnoy’s solution for 10 minutes. Cells 
were subsequently washed with 100% ethanol, 95% ethanol, and 70% ethanol for 10 minutes 
each and maintained in 70% ethanol until staining was initiated. For staining, cells were first 
rehydrated in nanopure water for 3 minutes and then stained in high iron diamine (HID) for 16 h 
[33]. Following HID staining, cells were washed for 5 minutes in tap H2O, stained with alcian 
blue (pH 2.5) for 5 minutes, and washed for 3 minutes in tap H2O. Cells were then 
counterstained with nuclear fast red for 1 minute and rinsed 5 minutes in tap H2O. Stained cells 
were dehydrated in increasing concentrations of ethanol and cleared in xylene. Glass coverslips 
were mounted onto slides with Permount (Fisher). Slides were scanned at 40X using the 
Nanozoomer Digital Pathology System (Hamamatsu). Twenty images were selected from each 
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well at 20X resolution for analysis. Images were imported into Axiovision 4.7 software (Zeiss) 
and the area of sulfomucin staining was selected and measured in µm2 in each image using the 
Automeasure module. The total area of cells in the image was measured in µm2 and used to 
normalize the area of sulfomucin staining.  
 
Analysis of Sulfo LeaAntigen Expression via Immunofluorescent Staining. LS174T cells were 
seeded in 8-well µ-slides (IBIDI) at a density of 6 x 104 cells/well and allowed to grow for 48 h. 
Cells were then washed twice with 1X HBSS (without phenol red), and fresh antibiotic-free 
media (without phenol red) containing flagellin, IL-13, or TNFα were added to the cells. After 
48 h, cells were washed 3X in 1X PBS and fixed with 4% paraformaldehyde (Electron 
Microscopy Sciences) for 20 minutes. Following fixation, cells were washed 3X in 1X PBS for 5 
minutes each, incubated in 0.1% Triton X-100 for 15 minutes to permeabilize cells, and rinsed 
3X in 1X PBS. Blocking was performed for 30 minutes in 5% normal goat serum (Vector 
Laboratories) and 5% IgG-Free BSA (Jackson ImmunoResearch Laboratories) in 1X PBS. Cells 
were rinsed once in 1X PBS, incubated for 2 h at room temperature with a mouse monoclonal 
[F2] antibody to Sulfo Lea (Abcam) diluted 1:60 in 10% blocking solution, and washed 3X in 
1XPBS for 5 minutes each. Incubation with Alexa Fluor 647 Goat Anti-Mouse IgM (H+L) 
(Invitrogen) diluted 1:200 in 10% blocking solution was performed for 2 h at room temperature 
and followed by 3 washes with 1X PBS for 5 minutes each. Cells were counterstained with 10 
µg/mL of DAPI (Invitrogen) for 15 minutes, rinsed 3X in 1X PBS, and covered with Prolong 
Gold Antifade Reagent (Invitrogen). After allowing Prolong Gold to cure for 24 h in the dark at 
room temperature, stained cells were stored in the dark at 4oC prior to imaging. Stained cells 
were imaged with a Zeiss LSM 710 confocal microscope using the 40X water objective and Zen 
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2008 software (Zeiss). Nine 2 x 2 tiled z-stacked images were collected from each well. Images 
were imported into Imaris (Bitplane) for reconstruction into 3-D isosurfaces. Volume of Sulfo 
Lea staining was measured in each image in µm3 and normalized to volume of stained nuclei in 
each image in µm3.  
 
Statistical Analysis. ANOVA and Fisher's protected least significant difference (FLSD) test were 
used to compare differences. These analyses were carried out using SAS software (Statview, 
Version 5.0.1; SAS Institute, Cary, NC). Differences were considered significant at p < 0.05. 
 
RESULTS 
TLR Expression in LS174T Cells. The expression of TLRs 1-10 at the mRNA level was 
examined in LS174T cells using conventional RT-PCR. As shown in Figure 3.1, all TLRs were 
detected in LS174T cells. There was some genomic DNA contamination in reactions for TLR3 
and -6, but amplicons using cDNA were still distinguishable. Multiple bands were observed for 
TLR9, including an amplicon of expected size. Expression of TLR3 and TLR5 was greatest while 
expression for TLR4 and TLR10 was the weakest. 
 
IL-8 Secretion from LS174T Cells. IL-8 secretion was measured in conditioned media following 
treatment with flagellin, IL-13, and TNFα for 24 h. This was done to determine whether cells 
were responding to the flagellin and TNFα treatments. As indicated in Figure 3.2, treatments 
with flagellin at 500 ng/mL and 1000 ng/mL resulted in a significant increase in IL-8 secretion 
from LS174T cells. Treatment with TNFα from 10 ng/mL to 1000 ng/mL also significantly 
increased IL-8 secretion from LS174T cells. These results indicate that cells were indeed 
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responding to both flagellin and TNFα. IL-13, on the other hand, produced a decrease in IL-8 
secretion at the two highest concentrations examined. 
 
Validation of Primers for Gene Expression Studies in LS174T Cells. All primers used for 
quantitative RT-PCR were shown to produce a single amplicon (Figures 3.3A and 3.4A) of 
expected size (Table 3.1) by conventional RT-PCR and a single peak upon dissociation curve 
analysis following quantitative RT-PCR (Figures 3.3B and 3.4B). Data are not shown for 
housekeeping genes, RPLP0 and GAPDH, but primers were equivalently validated. 
 
Expression of Sulfotransferases CHST5 and GAL3ST2 in Duodeum, Rectum, and Liver. 
Conventional RT-PCR was performed using human RNA from duodenum, rectum, and liver 
purchased from Stratagene. As shown in Figure 3.4C, CHST5 is expressed in duodenum, 
rectum, and liver while GAL3ST2 is only expressed in the rectum. The level of CHST5 
expression in liver appeared to be less than that in duodenum and rectum. 
 
Expression of Goblet Cell Secretory Product Genes in Response to Flagellin, IL-13, and TNFα. 
Gene expression for MUC2, RETNLB, and TFF3 was examined in LS174T cells following 
treatment with flagellin, IL-13, or TNFα for 24 h (Figure 3.5). MUC2 was increased by all three 
treatments with flagellin and IL-13 producing up to a 4-fold increase in gene expression, and 
TNFα producing up to a 5.5-fold increase in gene expression. RETNLB expression was 
decreased approximately 2-fold by the three lowest concentrations of IL-13 and approximately 
1.5 to 3-fold with increasing concentrations of TNFα. Flagellin did not significantly alter 
RETNLB expression. All concentrations of TNFα examined and 1000 ng/mL of flagellin lead to 
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a 1.5-fold increase in TFF3 expression. TFF3 was also increased 1.5 to 1.7 fold by all but the 
highest concentration of IL-13.  
 
Expression of Golgi Sulfotransferases, CHST5 and GAL3ST2, in Response to Flagellin, IL-13, 
and TNFα. Gene expression for CHST5 and GAL3ST2 was measured in LS174T cells following 
treatment with flagellin, IL-13, or TNFα for 24 h (Figure 3.6). IL-13 increased CHST5 
expression in a dose dependent manner up to 7.5-fold for the highest concentration. Flagellin did 
not significantly affect CHST5 expression, and treatment with TNFα resulted in only a 1.4-fold 
increase in CHST5 expression at the two lowest concentrations. GAL3ST2 expression was 
significantly increased by the two highest concentrations of IL-13 (2 to 3-fold) and flagellin (2 to 
2.5-fold). GAL3ST2 expression was also increased approximately 3-fold by treatment with 10 
ng/mL to 1000 ng/mL of TNFα. 
 
Expression of CDX2 and TLR5 in Response to Flagellin, IL-13, and TNFα. Gene expression for 
CDX2 and TLR5 was analyzed in LS174T cells following treatment with flagellin, IL-13, or 
TNFα for 24 h (Figure 3.7). Expression of CDX2 was only increased by treatment with 100 
ng/mL of IL-13 (1.6-fold) and 10 ng/mL of TNFα (1.1-fold). TLR5 expression was increased 
approximately 2-fold by treatment with 500 and 1000 ng/mL of flagellin.  Treatment with 5, 10, 
and 100 ng/mL of IL-13 also significantly increased TLR5 expression up to 2-fold. Treatment 
with TNFα increased TLR5 expression at concentrations of 10, 100, and 1000 ng/mL and 
produced up to a 3.7-fold increase in TLR5 expression. 
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Sulfomucin Expression in LS174T cells in Response to Flagellin, IL-13, and TNFα. Sulfomucin 
was identified by HID/AB staining of LS174T cells as shown in Figure 3.8 following treatment 
with various concentrations of flagellin, IL-13, and TNFα for 48 h. The area of sulfomucin 
staining in each image was measured and normalized to the area of cells in the image. 
Comparison between treated and control cells revealed a significant increase in sulfomucin 
expression in cells treated with 5 and 100 ng/mL of IL-13 and 1000 ng/mL of flagellin (Figure 
3.9). Measurable increases in sulfomucin expression were not observed in LS174T cells treated 
with any of the TNFα concentrations examined. 
 
Sulfo LeaAntigen Expression in LS174T cells in Response to Flagellin, IL-13, and TNFα. To 
examine effects of flagellin, IL-13, and TNFα on Sulfo Lea antigen expression, LS174T cells 
were treated with 500 ng/mL of flagellin, 100 ng/mL of IL-13, or 100 ng/mL of TNFα for 48 h. 
These concentrations were selected based on the lowest concentrations of flagellin, IL-13, and 
TNFα that produced the maximal increase in GAL3ST2 expression at 24 h (See Figure 3.6). A 
representative z-stacked, tiled image of the immunofluorescent staining is shown in Figure 
3.10A and a 3-D isosurface generated from that data is shown in Figure 3.10B. Comparison of 
the volume of Sulfo Lea staining per volume of nuclear staining between treatments revealed an 
increase in Sulfo Lea expression in LS174T cells treated with 500 ng/mL of flagellin for 48 h, 
while treatment with IL-13 or TNFα  did not significantly alter the level of Sulfo Lea expression 
(Figure 3.10C).  
 
Summary of Results. A summary of the results of measured end points is provided in Table 3.2. 
 
97 
 
DISCUSSION 
 The factors contributing to expression of specific mucin chemotypes are poorly 
understood, but there is evidence for the involvement of both host and microbial factors. In this 
study, we focused on the role of bacterial flagellin, IL-13, and TNFα in mucin sulfation. Gene 
expression for human TLRs 1-10 was analyzed in LS174T cells to aid in the selection of a 
microbial factor and revealed the expression of all ten human TLR genes by this cell line. This 
finding may reflect the importance of goblet cells in mediating host-microbe interactions in the 
intestinal epithelium. Expression of certain TLRs appeared to be greater than others, with TLR5 
being among the most abundantly expressed. For this reason, flagellin, a known agonist of TLR5 
[34], was selected as the microbial factor for this study.  
LS174T cells constitutively secrete mucin, which may make them more resistant to 
certain treatments. Previous studies have shown TNFα to induce IL-8 secretion from LS174T 
cells and bacterial flagellin to be a strong inducer of IL-8 secretion from intestinal epithelial 
cells, but flagellin had not been previously tested in this cell line [34, 35]. Therefore, to confirm 
that LS174T cells were responding to flagellin and TNFα, IL-8 secretion was measured in 
conditioned media following stimulus with flagellin and TNFα for 24 h.  The increased secretion 
of IL-8 indicated that the LS174T cell line was indeed responsive to both flagellin and TNFα. 
On the other hand, IL-13 treatment decreased IL-8 secretion at higher concentrations. These 
results are consistent with a previous report that IL-13 reduced IL-8 secretion by human 
intestinal epithelial cells [36]. 
Flagellin, IL-13, and TNFα all upregulated expression of MUC2, indicating that 
increased mucin production is a common response to these stimuli. The increase in MUC2 
expression in response to IL-13 and TNFα is consistent with published work in the LS174T cell 
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line showing IL-13 and TNFα increase MUC2 expression via a mitogen-activated protein (MAP) 
kinase pathway [37]. To our knowledge, this is the first study to report an increase in MUC2 
expression by an intestinal epithelial cell line in response to flagellin from S. typhimurium. 
Flagellin isolated from P. aeruginosa was, however, previously found to activate MUC2 
transcription via downstream signaling following binding to the surface glycolipid receptor, 
Asialo-GM1, and requiring intact functioning of TLR5 [38, 39]. 
To determine whether there was a general increase in the expression of goblet cell 
secretory product genes, expression of RETNLB and TFF3 were also examined. Similar to results 
with MUC2, flagellin, IL-13 and TNFα all upregulated expression of TFF3, but the response was 
much less than that observed with MUC2. The enhanced expression of TFF3 as a result of IL-13 
treatment is in accord with work done in HT29 CL.16E cells, which develop a goblet-cell like 
phenotype after reaching confluence [20]. However, our results with TNFα are in contrast to 
another study showing a dramatic reduction in TFF3 expression in the HT-29 cell line in 
response to this proinflammatory cytokine [40]. The use of a different cell line is one possible 
explanation for the contrasting results. Both IL-13 and TNFα caused a downregulation in 
RETNLB expression while flagellin did not alter expression levels significantly from the control. 
The results for IL-13 and TNFα are surprising considering that previous studies demonstrated 
increased RETNLB expression in LS174T cells treated with IL-13 or TNFα [21, 41, 42]. 
Analysis of RETNLB expression after shorter and longer treatment times with IL-13 and TNFα 
might help to clarify the conflicting results. The effects of bacterial flagellin on RETNLB 
expression had not been previously examined, but LPS was shown in an earlier study to 
upregulate expression of RETNLB indicating that other microbial components may have a greater 
influence on RETNLB expression [41]. Overall, our results demonstrate the increase in MUC2 
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expression elicited by flagellin, IL-13, and TNFα was not due to a common upregulation of 
goblet cell secretory product genes. Furthermore, TFF3 expression was similarly unregulated, 
but to a lesser extent, while expression of RETNLB did not follow this trend and was instead 
decreased or unaltered in response to the treatments.  
The expression of sulfotransferases, CHST5 and GAL3ST2, was examined in RNA 
isolated from human duodenum, rectum, and liver. CHST5 was expressed in all three tissues 
while GAL3ST2 was only expressed in the rectum. The presence of CHST5 in the small intestine 
and rectum is consistent with a previous study [28], but this finding indicates that GAL3ST2 is 
likely the more important sulfotransferase for biosynthesis of sulfomucin seen in the colon, 
since, based on histochemical staining, human small intestine does not typically express 
sulfomucin [43].  
Enhancement of GAL3ST2 expression was observed in LS174T cells following treatment 
with flagellin, IL-13, and TNFα for 24 h indicating that increased mucin sulfation at the C-3 
position of Gal might be a common response to inflammatory stimuli. Analysis of CHST5 
expression revealed IL-13 to be a strong inducer of expression in a dose dependent manner, 
flagellin to not significantly alter expression, and TNFα to minimally increase expression at low 
concentrations. This observation is consistent with the possibility that mucin sulfation at the C-6 
position of N-acetylglucosamine is augmented in response to IL-13. To determine whether 
increased expression of these sulfotransferases corresponded to an increase in mucin sulfation, 
sulfomucin associated with the cells (identified by HID/AB staining) and expression of the Sulfo 
Lea antigen, which is synthesized in part by GAL3ST2 [44], were measured in cells after 48 h of 
treatment with selected concentrations of flagellin, IL-13, and TNFα. Overall sulfomucin was 
increased by flagellin and IL-13 but remained unchanged by TNFα. Only exposure to flagellin 
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increased the expression of the Sulfo Lea antigen. Together, these results indicate that IL-13 may 
increase sulfomucins primarily via increased expression of CHST5, while flagellin may increase 
sulfomucins, including those with the Sulfo Lea antigen, by enhancing expression of GAL3ST2. 
Although TNFα increased expression of both sulfotransferase genes, it did not increase 
sulfomucin content during the time period examined. It is possible that the increased expression 
of GAL3ST2 seen with IL-13 and TNFα treatment would have resulted in increased Sulfo Lea 
antigen with extended treatment or that Sulfo Lea antigen was increased by both of these, but that 
mucin containing the Sulfo Lea antigen was secreted into the media. Both IL-13 and TNFα have 
been shown to induce mucin secretion from LS174T cells [37]. Thus additional studies, 
measuring secreted sulfomucin, are needed to fully examine the effects of flagellin, IL-13 and 
TNFα on sulfomucins. 
The upregulation of MUC2 and GAL3ST2 in response to flagellin, IL-13, and TNFα 
suggests that intestinal goblet cells attempt to upregulate sulfomucin biosynthesis in response to 
microbial and inflammatory stimuli, perhaps in an attempt to increase host protection. This is in 
accord with the idea that sulfomucins are protective because they increase mucus viscosity and 
resistance to bacterial degradation and microbe adhesion [45]. The results with TNFα are of 
particular interest because of its association with IBD and the reduced mucin sulfation seen with 
active IBD. Consistent with the idea that individuals with IBD mount an inappropriate immune 
response [46], it may be that those with IBD do not respond appropriately to TNFα and thus do 
not increase sulfomucin. The same may also be true of their response to microbial-derived 
factors, such as flagellin. One study reported that sulfomucins are preferentially secreted by 
individuals with ulcerative colitis while sulfate incorporation into mucins is reduced [47]. Thus, 
it may be that TNFα, either as a normal or abnormal response, also elicits a preferential secretion 
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of sulfated mucins so that sulfomucins are eventually depleted within goblet cells. Alternatively, 
since we use a transformed cell line for this study, it could be that the responses we observed 
with LS174T cell exposure to flagellin, IL-13, and TNFα, are not what typically occur in normal 
healthy colon. Further studies should be conducted to determine whether responses are consistent 
in situ or in non-transformed cells.  
Additional studies are also needed to better understand the mechanisms by which 
flagellin, IL-13, and TNFα enhance expression of specific sulfotransferases and sulfomucin 
production. Previous studies have identified pathways governing goblet cell secretory product 
gene expression in response to TNFα and IL-13 [37, 48-50]. These pathways may be similarly 
involved in regulation of CHST5 and GAL3ST2 transcription. We did examine gene expression 
of the transcription factor CDX2, which has been shown to transactivate the promoters of MUC2, 
RETNLB, and TFF3 [51-53]. We found CDX2 to be upregulated in response to IL-13 exposure. It 
is possible that CDX2 may also transactivate CHST5 or even GAL3ST2, and it would be 
beneficial to establish whether there are CDX2 binding sites within their promoter regions. The 
mechanisms of flagellin’s effects on goblet cell secretory products and the sulfotransferases, 
especially need to be further studied to determine whether changes are a direct response 
involving TLR signaling in intestinal goblet cells or whether IL-8 or other inflammatory cues 
might be triggering the goblet cell response to flagellin. We observed an upregulation of TLR5 
expression with the concentrations of flagellin that induced IL-8 secretion and MUC2 and 
GAL3ST2 expression. However, a similar upregulation of TLR5 expression was also seen with 
IL-13 and TNFα, so the significance of this finding is uncertain. 
In summary, our results indicate that flagellin, IL-13, and TNFα have differential effects 
on mucin sulfotransferases and sulfation as well as the goblet cell secretory product genes. All 
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three stimuli significantly increase MUC2 expression. IL-13 increases sulfomucin most likely via 
increased expression of CHST5, while flagellin increases sulfomucin possibly by increasing 
expression of GAL3ST2. Although TNFα increased expression of both sulfotransferase genes, it 
did not increase sulfomucin content during the time period examined. Together these data 
indicate that both host and microbial factors influence mucin chemotypes. Additional studies are 
needed to understand the mechanisms underlying these results and their role in the reduced 
mucin sulfation observed in IBD. 
 
REFERENCES 
 
1. Baumgart, D.C. and W.J. Sandborn, Inflammatory bowel disease: clinical aspects and 
established and evolving therapies. Lancet, 2007. 369(9573): p. 1641-57. 
2. Campbell, B.J., L.G. Yu, and J.M. Rhodes, Altered glycosylation in inflammatory bowel 
disease: a possible role in cancer development. Glycoconj J, 2001. 18(11-12): p. 851-8. 
3. Shirazi, T., et al., Mucins and inflammatory bowel disease. Postgrad Med J, 2000. 
76(898): p. 473-8. 
4. Strugala, V., P.W. Dettmar, and J.P. Pearson, Thickness and continuity of the adherent 
colonic mucus barrier in active and quiescent ulcerative colitis and Crohn's disease. Int J 
Clin Pract, 2008. 62(5): p. 762-9. 
5. Swidsinski, A., et al., Comparative study of the intestinal mucus barrier in normal and 
inflamed colon. Gut, 2007. 56(3): p. 343-50. 
6. Arnold, J.W., G.R. Klimpel, and D.W. Niesel, Tumor necrosis factor (TNF alpha) 
regulates intestinal mucus production during salmonellosis. Cell Immunol, 1993. 151(2): 
p. 336-44. 
7. Deplancke, B. and H.R. Gaskins, Microbial modulation of innate defense: goblet cells 
and the intestinal mucus layer. Am J Clin Nutr, 2001. 73(6): p. 1131S-1141S. 
103 
 
8. Groux-Degroote, S., et al., IL-6 and IL-8 increase the expression of glycosyltransferases 
and sulfotransferases involved in the biosynthesis of sialylated and/or sulfated Lewisx 
epitopes in the human bronchial mucosa. Biochem J, 2008. 410(1): p. 213-23. 
9. Conour, J.E., et al., Acidomucin goblet cell expansion induced by parenteral nutrition in 
the small intestine of piglets. Am J Physiol Gastrointest Liver Physiol, 2002. 283(5): p. 
G1185-96. 
10. Enss, M.L., et al., Proinflammatory cytokines trigger MUC gene expression and mucin 
release in the intestinal cancer cell line LS180. Inflamm Res, 2000. 49(4): p. 162-9. 
11. Hill, R.R., H.M. Cowley, and A. Andremont, Influence of colonizing micro-flora on the 
mucin histochemistry of the neonatal mouse colon. Histochem J, 1990. 22(2): p. 102-5. 
12. Enss, M.L., et al., Effects of perorally applied endotoxin on colonic mucins of germfree 
rats. Scand J Gastroenterol, 1996. 31(9): p. 868-74. 
13. Liau, Y.H., et al., Helicobacter pylori lipopolysaccharide effect on the synthesis and 
secretion of gastric sulfomucin. Biochem Biophys Res Commun, 1992. 184(3): p. 1411-
7. 
14. Sheahan, D.G. and H.R. Jervis, Comparative histochemistry of gastrointestinal 
mucosubstances. Am J Anat, 1976. 146(2): p. 103-31. 
15. Majuri, M.L., et al., Expression and function of alpha 2,3-sialyl- and alpha 1,3/1,4-
fucosyltransferases in colon adenocarcinoma cell lines: role in synthesis of E-selectin 
counter-receptors. Int J Cancer, 1995. 63(4): p. 551-9. 
16. Delmotte, P., et al., Influence of TNFalpha on the sialylation of mucins produced by a 
transformed cell line MM-39 derived from human tracheal gland cells. Glycoconj J, 
2001. 18(6): p. 487-97. 
17. Karlsson, N.G., et al., Identification of transient glycosylation alterations of sialylated 
mucin oligosaccharides during infection by the rat intestinal parasite Nippostrongylus 
brasiliensis. Biochem J, 2000. 350 Pt 3: p. 805-14. 
104 
 
18. Ishikawa, N., Y. Horii, and Y. Nawa, Immune-mediated alteration of the terminal sugars 
of goblet cell mucins in the small intestine of Nippostrongylus brasiliensis-infected rats. 
Immunology, 1993. 78(2): p. 303-7. 
19. Soga, K., et al., Alteration of the expression profiles of acidic mucin, sialytransferase, 
and sulfotransferases in the intestinal epithelium of rats infected with the nematode 
Nippostrongylus brasiliensis. Parasitol Res, 2008. 103(6): p. 1427-34. 
20. Blanchard, C., et al., IL-4 and IL-13 up-regulate intestinal trefoil factor expression: 
requirement for STAT6 and de novo protein synthesis. J Immunol, 2004. 172(6): p. 3775-
83. 
21. Artis, D., et al., RELMbeta/FIZZ2 is a goblet cell-specific immune-effector molecule in 
the gastrointestinal tract. Proc Natl Acad Sci U S A, 2004. 101(37): p. 13596-600. 
22. Kanoh, A., et al., Interleukin-4 induces specific pp-GalNAc-T expression and alterations 
in mucin O-glycosylation in colonic epithelial cells. Biochim Biophys Acta, 2008. 
1780(3): p. 577-84. 
23. Takeda, K., et al., Direct effects of IL-4/IL-13 and the nematode Nippostrongylus 
brasiliensis on intestinal epithelial cells in vitro. Parasite Immunol. 32(6): p. 420-9. 
24. Brockhausen, I., Pathways of O-glycan biosynthesis in cancer cells. Biochim Biophys 
Acta, 1999. 1473(1): p. 67-95. 
25. Robbe, C., et al., Structural diversity and specific distribution of O-glycans in normal 
human mucins along the intestinal tract. Biochem J, 2004. 384(Pt 2): p. 307-16. 
26. Seko, A., et al., Down-regulation of Gal 3-O-sulfotransferase-2 (Gal3ST-2) expression in 
human colonic non-mucinous adenocarcinoma. Jpn J Cancer Res, 2002. 93(5): p. 507-15. 
27. Lee, J.K., et al., Activities and expression pattern of the carbohydrate sulfotransferase 
GlcNAc6ST-3 (I-GlcNAc6ST): functional implications. Glycobiology, 2003. 13(4): p. 
245-54. 
105 
 
28. Nishimura, M. and S. Naito, Tissue-specific mRNA expression profiles of human 
carbohydrate sulfotransferase and tyrosylprotein sulfotransferase. Biol Pharm Bull, 
2007. 30(4): p. 821-5. 
29. Tom, B.H., et al., Human colonic adenocarcinoma cells. I. Establishment and description 
of a new line. In Vitro, 1976. 12(3): p. 180-91. 
30. Gottke, M.U., et al., Functional heterogeneity of colonic adenocarcinoma mucins for 
inhibition of Entamoeba histolytica adherence to target cells. J Eukaryot Microbiol, 
1998. 45(2): p. 17S-23S. 
31. Sands, B.E., et al., Molecular cloning of the rat intestinal trefoil factor gene. 
Characterization of an intestinal goblet cell-associated promoter. J Biol Chem, 1995. 
270(16): p. 9353-61. 
32. Omueti, K.O., et al., Domain exchange between human toll-like receptors 1 and 6 reveals 
a region required for lipopeptide discrimination. J Biol Chem, 2005. 280(44): p. 36616-
25. 
33. Spicer, S.S., Diamine Methods for Differentialing Mucosubstances Histochemically. J 
Histochem Cytochem, 1965. 13: p. 211-34. 
34. Gewirtz, A.T., et al., Salmonella typhimurium translocates flagellin across intestinal 
epithelia, inducing a proinflammatory response. J Clin Invest, 2001. 107(1): p. 99-109. 
35. Barshishat, M., et al., TNFalpha and IL-8 regulate the expression and function of CD44 
variant proteins in human colon carcinoma cells. Clin Exp Metastasis, 2002. 19(4): p. 
327-37. 
36. Lugering, N., et al., Interleukin (IL)-13 and IL-4 are potent inhibitors of IL-8 secretion by 
human intestinal epithelial cells. Dig Dis Sci, 1999. 44(3): p. 649-55. 
37. Iwashita, J., et al., mRNA of MUC2 is stimulated by IL-4, IL-13 or TNF-alpha through a 
mitogen-activated protein kinase pathway in human colon cancer cells. Immunol Cell 
Biol, 2003. 81(4): p. 275-82. 
106 
 
38. McNamara, N., et al., AsialoGM1 and TLR5 cooperate in flagellin-induced nucleotide 
signaling to activate Erk1/2. Am J Respir Cell Mol Biol, 2006. 34(6): p. 653-60. 
39. Dharmani, P., et al., Role of intestinal mucins in innate host defense mechanisms against 
pathogens. J Innate Immun, 2009. 1(2): p. 123-35. 
40. Loncar, M.B., et al., Tumour necrosis factor alpha and nuclear factor kappaB inhibit 
transcription of human TFF3 encoding a gastrointestinal healing peptide. Gut, 2003. 
52(9): p. 1297-303. 
41. He, W., et al., Bacterial colonization leads to the colonic secretion of RELMbeta/FIZZ2, 
a novel goblet cell-specific protein. Gastroenterology, 2003. 125(5): p. 1388-97. 
42. Fujio, J., et al., Regulation of gut-derived resistin-like molecule beta expression by 
nutrients. Diabetes Res Clin Pract, 2008. 79(1): p. 2-10. 
43. Filipe, M.I., Mucins in the human gastrointestinal epithelium: a review. Invest Cell 
Pathol, 1979. 2(3): p. 195-216. 
44. Loveless, R.W., et al., Monoclonal antibody 91.9H raised against sulfated mucins is 
specific for the 3'-sulfated Lewisa tetrasaccharide sequence. Glycobiology, 1998. 8(12): 
p. 1237-42. 
45. Nieuw Amerongen, A.V., et al., Sulfomucins in the human body. Biol Chem, 1998. 
379(1): p. 1-18. 
46. Strober, W., I. Fuss, and P. Mannon, The fundamental basis of inflammatory bowel 
disease. J Clin Invest, 2007. 117(3): p. 514-21. 
47. Van Klinken, B.J., et al., Sulphation and secretion of the predominant secretory human 
colonic mucin MUC2 in ulcerative colitis. Gut, 1999. 44(3): p. 387-93. 
48. Ahn, D.H., et al., TNF-alpha activates MUC2 transcription via NF-kappaB but inhibits 
via JNK activation. Cell Physiol Biochem, 2005. 15(1-4): p. 29-40. 
107 
 
49. Stutz, A.M., et al., The Th2 cell cytokines IL-4 and IL-13 regulate found in inflammatory 
zone 1/resistin-like molecule alpha gene expression by a STAT6 and CCAAT/enhancer-
binding protein-dependent mechanism. J Immunol, 2003. 170(4): p. 1789-96. 
50. Wang, M.L., et al., Immune-mediated signaling in intestinal goblet cells via PI3-kinase- 
and AKT-dependent pathways. Am J Physiol Gastrointest Liver Physiol, 2008. 295(5): p. 
G1122-30. 
51. Silberg, D.G., et al., Cdx1 and cdx2 expression during intestinal development. 
Gastroenterology, 2000. 119(4): p. 961-71. 
52. Wang, M.L., et al., Regulation of RELM/FIZZ isoform expression by Cdx2 in response to 
innate and adaptive immune stimulation in the intestine. Am J Physiol Gastrointest Liver 
Physiol, 2005. 288(5): p. G1074-83. 
53. Yamamoto, H., Y.Q. Bai, and Y. Yuasa, Homeodomain protein CDX2 regulates goblet-
specific MUC2 gene expression. Biochem Biophys Res Commun, 2003. 300(4): p. 813-8. 
 
54. Johnson, C.M. and R.I. Tapping, Microbial products stimulate human Toll-like receptor 
2 expression through histone modification surrounding a proximal NF-kappaB-binding 
site. J Biol Chem, 2007. 282(43): p. 31197-205. 
 
55.  Rozen, S. and H. J. Skaletsky. Primer3 on the WWW for general users and for biologist 
programmers. In: Bioinformatics Methods and Protocols: Methods in Molecular Biology. 
Krawetz S, Misener S., Eds., 2000. Humana Press, Totowa, NJ, p. 365-386. Source code 
available at http://fokker.wi.mit.edu/primer3/. 
 
56. Dydensborg, A.B., et al., Normalizing genes for quantitative RT-PCR in differentiating 
human intestinal epithelial cells and adenocarcinomas of the colon. Am J Physiol 
Gastrointest Liver Physiol, 2006. 290(5): p. G1067-74. 
108 
 
FIGURES AND TABLES 
 
 
109 
 
 
110 
 
 
 
 
111 
 
 
112 
 
 
113 
 
 
114 
 
 
115 
 
 
 
 
 
 
 
 
 
 
 
116 
 
 
117 
 
 
 
118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
Chapter 4 
CYSTEINE DIOXYGENASE EXPRESSION IN THE INTESTINAL EPITHELIUM 
 
ABSTRACT 
Cysteine dioxygenase (CDO) catalyzes the oxidation of cysteine to cysteine sulphinic 
acid, which is the first and rate limiting step for cysteine utilization. Mammals regulate cysteine 
metabolism through CDO to maintain sufficient cysteine for protein synthesis and production of 
other essential molecules such as glutathione, taurine, pyruvate and inorganic sulfate, but below 
the threshold for cytotoxicity. While CDO is known to be highly expressed in liver, its 
expression in the intestine remains uncharacterized. Here, CDO expression and localization in 
mouse small and large intestine is examined using immunohistochemical and 
immunofluorescence staining techniques. Adult mouse duodenum, jejunum, ileum, and proximal 
and distal colon were stained with an anti-CDO antibody and analyzed microscopically. 
Additional sections were stained using two-color immunofluorescence for CDO and matrix 
metalloproteinase 7 (MMP-7), a marker of Paneth cells, or chromagranin A (ChrA), a marker of 
enteroendocrine cells. Immunohistochemical analysis of mouse intestine revealed positive CDO 
staining in goblet cells, Paneth cells (small intestine only), and enteroendocrine cells while CDO 
staining was notably absent in absorptive epithelium. Dual immunofluorescent staining for CDO 
and ChrA or MMP-7 confirmed CDO expression in mouse enteroendocrine cells and Paneth 
cells, respectively. These results demonstrate that CDO expression in mouse small and large 
intestine is restricted to cells of the secretory lineage. This striking difference in CDO expression 
between the absorptive and secretory cell lineages is likely due to higher cysteine catabolism 
requirements in goblet, Paneth, and enteroendocrine cells relative to absorptive epithelial cells 
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either to synthesize additional taurine and sulfate or to metabolize excess cysteine when cells are 
not actively synthesizing cysteine-rich secretory products.                                 
 
INTRODUCTION 
Cysteine dioxygenase (CDO, EC 1.13.11.20) catalyzes the first and rate-limiting step of 
cysteine catabolism, which is the oxidation of cysteine (Cys) to cysteinesulfinate (Figure 4.1) [1, 
2]. Cysteinesulfinate is further metabolized to yield a number of important products, including 
hypotaurine/taurine, pyruvate and sulfate (Figure 4.1). Mammals regulate cysteine metabolism 
through CDO to maintain cysteine levels within a limited range. Cysteine concentrations must be 
maintained at an adequate level to meet requirements for the synthesis of proteins and other 
essential molecules such as glutathione, coenzyme A, taurine, and inorganic sulfur while being 
kept below the threshold of cytotoxicity [1, 3, 4]. The toxicity of cysteine has been demonstrated 
in multiple animal models [5-7], and chronically elevated levels of cysteine have been associated 
with neurodegenerative and autoimmune diseases, including Parkinson’s Disease [8], 
Alzheimer's disease [8], rheumatoid arthritis [9], and systemic lupus erythematosus [10]. Thus, 
CDO may have important implications in disease. In fact, a decline in CDO activity has been 
associated with the neurological disorder pantothenate kinase-associated neurodegeneration 
(PKAN) formerly known as Hallervorden-Spatz disease and characterized by degeneration of 
principal movement centers in the brain [11, 12].  
Rodent and human CDO gene expression has been reported in a number of tissues [13-
17], indicating the importance of CDO in whole body cysteine homeostasis. However, highest 
mRNA levels of CDO were present in the liver in rats, mice, and humans. Regarding intestinal 
tissue, CDO mRNA was detected in whole tissue homogenates of mouse small intestine but 
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found to be quite low and did not appear to be detected at the protein level [13]. A recently 
published paper, though, demonstrated low, but detectable CDO expression at the protein level in 
both mouse duodenum and colon [18]. Published studies examining CDO expression in rat or 
human small intestine or colon at the mRNA level could not be found, although an earlier study 
reported that rat enterocytes could metabolize cysteine to cysteinesulfinate via CDO [19]. 
However, a recent report described the localization of CDO specifically to goblet cells in the rat 
small intestine [20]. Published descriptions of CDO localization in the colon were also not found. 
The aim of this study was to characterize the cell types that express CDO in mouse small 
intestinal and colonic epithelium. The epithelium in the small intestine and colon consists of 
absorptive and secretory cells, which derive from a common precursor cell [21]. The secretory 
lineage consists of goblet cells and enteroendocrine cells in both the small intestine and colon 
and includes Paneth cells in the small intestine. Since CDO was reported to be expressed in rat 
goblet cells, we sought to determine whether this was also true in mouse intestine and whether 
CDO expression was common among cells of the secretory lineage. 
  
MATERIALS AND METHODS 
Collection of Mouse Tissues. Procedures were approved by the University of Illinois Institutional 
Animal Care and Use Committee. Small intestine, colon, and cecum were harvested from adult 
male B6EiC3Sn a/A-Otc+ mice and fixed in Carnoy’s solution for two hours. Fixed tissues were 
subsequently processed, embedded in paraffin, and sectioned onto glass slides.  
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CDO Immunohistochemistry. After deparaffinization, endogenous peroxidases were blocked by 
immersion in 0.5% hydrogen peroxide in methanol for 10 minutes. Sections were then blocked 
with 10% goat serum (Vector Laboratories) in 2X casein (Vector Laboratories) for 20 minutes 
prior to incubation with a 1:50 dilution in 1X casein of an affinity-purified rabbit anti-rat CDO 
antibody [16] for 2 hours at 37oC. After washing, sections were sequentially incubated with 
biotinylated goat anti-rabbit IgG antibody (1:200 dilution in 1X casein) for 20 min at room 
termperature, peroxidase-labeled avidin-biotin complex for 30 min at room temperature, and 
DAB substrate (Vector Laboratories) for approximately 5 min color development. Sections were 
counterstained with Mayer’s hematoxylin (Sigma), washed in tap H2O, dehydrated, cleared in 
xylene, and mounted with Permount (Fisher). Biotinylated goat anti-rabbit IgG antibody and 
peroxidase-labeled avidin-biotin complex were part of a Rabbit IgG VECTSTAIN Elite ABC Kit 
(Vector Laboratories). Slides were imaged using a Zeiss Axiovert 200M microscope and 
Axiovision 4.7 software. 
 
Immunofluorescence. Deparaffinized sections were blocked with 5% donkey serum (Jackson 
ImmunoResearch Laboratories) and 5% IgG-Free BSA (Jackson ImmunoResearch Laboratories)  
for 30 minutes followed by incubation with a 1:50 dilution of rabbit anti-rat CDO antibody and 
either a 1:50 dilution of goat anti-mouse ChrA antibody (Santa Cruz Biotechnology) or goat anti-
mouse MMP-7 (R & D Systems) antibody for 2 hours at room temperature. Sections were 
washed 3X with 1X PBS for 5 min each and then sequentially incubated with a 1:200 dilution of 
Alexa Fluor 647 donkey anti-rabbit IgG (H+L) antibody (Invitrogen) for 1 hour, a 1:200 dilution 
of Alexa Fluor 546 donkey anti-goat IgG (H+L) antibody (Invitrogen) for 1 hour, and 10 µg/mL 
of DAPI (Invitrogen) for 15 min. Sections were washed 3X with 1X PBS for 5 min after 
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incubation with each antibody. Following counterstaining with DAPI, tissues were rinsed 3X in 
1X PBS and mounted with Prolong Gold Antifade Reagent (Invitrogen). After allowing Prolong 
Gold to cure for 24 hours in the dark at room temperature, stained cells were stored in the dark at 
4oC prior to imaging. Slides were imaged using a Zeiss Axiovert 200M microscope and 
Axiovision 4.7 software. 
 
RESULTS 
CDO Immunohistochemistry: Immunohistochemical staining revealed positive CDO staining in 
goblet cells but not enterocytes in mouse duodenum, jejunum, ileum, cecum, proximal colon, and 
distal colon (Figure 4.2). In the small intestine, positive CDO staining was also observed at the 
base of the crypts, which suggested staining of Paneth cells. In addition, positive CDO staining 
appeared to be present in fewer cells in the distal colon compared to the proximal colon. 
Preliminary studies in human right colon, left colon, and rectum have also indicated that CDO is 
expressed in secretory goblet cells but not absorptive cells (data not shown).  Initially, we used a 
secondary antibody-only negative control, which revealed no positive staining. Rabbit IgG 
(Vector Laboratories) was later tested as a negative control at the same IgG concentration as the 
CDO antibody. The rabbit IgG control produced some staining of goblet cells in small intestinal 
and colon tissue sections, but positive staining was absent from the small intestinal crypt base 
and was weaker and in fewer cells compared to staining with the anti-CDO antibody. 
Furthermore, CDO and rabbit IgG staining performed using another set of mouse small intestinal 
and colon tissues fixed in formalin and a modified protocol resulted in the same pattern of 
positive staining with the CDO antibody as with the Carnoy’s fixed tissues but no positive 
staining with the rabbit IgG control.  
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CDO Localization in Paneth Cells. To confirm that CDO was also expressed in Paneth cells, 
small intestinal tissue sections were simultaneously stained for CDO and MMP-7, a marker for 
Paneth cells [22]. As shown in Figure 4.3A, when images of CDO (red) and MMP-7 (green) 
staining in small intestine were merged, colocalization (yellow) of the two stains was observed at 
the base of the crypt. This observation along with the IHC images confirms that there is positive 
CDO staining within Paneth cells. However, from the high magnification image in Figure 4.3B, 
it appears that CDO and MMP-7 are not localized in exactly the same area within Paneth cells 
and there may also be some staining for CDO in between and adjacent to Paneth cells where 
populations of intestinal stem cells are located [23].  
 
CDO Localization in Enteroendocrine Cells. To determine whether the remaining member of the 
secretory lineage, the enteroendocrine cell, expressed CDO, small intestine, colon, and cecum 
were simultaneously stained for CDO and ChrA, a marker for enteroendocine cells [24]. Merged 
images of CDO (red) and ChrA (green) staining in small intestine, colon, and cecum demonstrate 
colocalization (yellow) of CDO in apparently all ChrA expressing cells (Figure 4.4A). Hence, 
CDO is also expressed in enteroendocrine cells. The high magnification image (Figure 4.4B) 
shows the CDO and ChrA are in a similar region of the enteroendocrine cell.   
 
DISCUSSION 
CDO is an important enzyme in regulating cysteine levels in the liver and possibly other 
tissues in the body. The enzyme had previously been detected in mouse small intestine and colon 
at the protein level [18], but information regarding its localization in the intestinal epithelium 
remained to be fully characterized. In this study, immunohistochemical staining for CDO 
126 
 
revealed localization of CDO to goblet cells in mouse colon and cecum and to Paneth and goblet 
cells in mouse small intestine. The localization of CDO to goblet cells was in accord with an 
earlier report describing CDO localization in rat small intestine [20]. Localization of CDO to 
Paneth cells as well as enteroendocrine cells was confirmed by dual immunofluorescent staining 
for CDO and markers for these two secretory cell types. Enteroendocrine cells in small intestine, 
colon, and cecum all expressed CDO. Overall, these results demonstrate that CDO expression in 
mouse small intestine, colon, and cecum is restricted to cells of the secretory lineage. There was 
some indication that CDO might also be expressed within intestinal stem cells, which would 
suggest that the secretory lineage may acquire CDO before differentiating into individual cell 
types. However, additional colocalization studies are needed to confirm the presence of CDO in 
intestinal stem cells.  
A major question to address is why cells of the secretory lineage would have a higher 
requirement for CDO than absorptive cells. One possible reason is a higher cysteine requirement 
in goblet, Paneth, and enteroendocrine cells relative to absorptive epithelial cells because of a 
greater requirement for cysteine for synthesizing secretory products. Goblet cells, in particular, 
synthesize and secrete multiple cysteine-rich products, including mucin 2 [25], resistin-like 
molecule beta [26], and trefoil factor 3 [27, 28]. Likewise, Paneth cells are known to secrete 
cysteine-rich α-defensins [29]. In liver, CDO is known to be highly regulated by cysteine 
availability [1]. Thus, CDO may provide secretory cells with a means for regulating cysteine 
levels to ensure ample cysteine for synthesis of secretory products while preventing cysteine 
levels from becoming cytotoxic. Comparison of cysteine metabolism in specific intestinal 
epithelial cell types and CDO expression in response to differing cysteine concentrations would 
provide more evidence for this hypothesis. 
127 
 
Alternatively, the secretory lineage could have a high requirement for end products of 
cysteine catabolism, which include sulfate and taurine. Goblet cells, for example, synthesize and 
secrete sulfomucins, and CDO catabolism of cysteine may be necessary to provide sufficient 
sulfate for sulfomucin biosynthesis. In adult mice, small intestinal and cecal goblet cells 
predominantly produce sulfated mucins, while proximal colon goblet cells primarily produce 
non-sulfated sialomucins, and distal colon goblet cells produce both sialo- and sulfomucins 
depending on their location along the crypt [30]. Since we observed abundant CDO expression in 
the proximal colon, it appears that CDO expression is not restricted to sulfomucin containing 
goblet cells. Thus, CDO may be expressed in goblet cells in order to catabolize cysteine to form 
sulfate for biosynthesis of sulfomucins, but this does not fully explain CDO localization to 
intestinal goblet cells or its localization in Paneth or enteroendocrine cells. 
Taurine can be synthesized from cysteine via oxidation by CDO to cysteine sulfinate, 
which is converted to hypotaurine by cysteinesulfinic acid decarboxylase (CSAD), and followed 
by hypotaurine oxidation to taurine via an unknown mechanism [31]. Consistent with CDO 
localization to goblet cells, taurine was reported to localize within the mucus granules of mouse 
intestinal goblet cells [32]. There was no mention of whether taurine was also present in other 
cells of the secretory lineage. Taurine has a number of cytoprotective properties, including 
antioxidant, anti-inflammatory, and osmoregulatory effects, which would make its production 
beneficial to secretory cells [33]. The osmoregulatory function of taurine might be especially 
important for secretory cells undergoing cell volume changes with release of secretory products. 
It should be noted, though, that taurine can be synthesized from cysteine via a CDO independent 
pathway as well, which involves cysteine conversion to Coenzyme A (CoA) followed by the 
degradation of CoA to cysteamine, which is then oxidized to hypotaurine/taurine via cysteamine 
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dioxygenase (ADO) [34]. Thus, future studies should be done to see whether the CDO/CSAD 
and/or ADO pathways for taurine biosynthesis are intact and functional in secretory cells and 
whether they are responsive to inflammatory triggers, oxidative stress, or osmotic changes. 
Experiments described in Chapter 5 indicate that the ADO pathway, and possibly the 
CDO/CSAD pathway, are intact and responsive to certain inflammatory stimuli in the human 
goblet cell-like LS174T cells. 
In summary, we observed that CDO expression in the small intestine and colon is 
restricted to secretory cells and not expressed by absorptive enterocytes. Additional studies are 
necessary to determine the functional significance of this finding and whether CDO expression is 
present in intestinal stem cell populations. 
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Chapter 5 
TAURINE BIOSYNTHESIS IN INTESTINAL GOBLET CELLS BY THE CYSTEINE 
DIOXYGENASE/CYSTEINESULFINATE DECARBOXYLASE AND CYSTEAMINE 
DIOXYGENASE PATHWAYS 
 
ABSTRACT 
Taurine, one of the most abundant amino acids in the body, has a number of important 
physiological functions, including antioxidant, anti-inflammatory, and osmoregulatory 
properties. It can be synthesized in mammals by 2 pathways. One pathway involves the oxidation 
of cysteine via cysteine dioxygenase (CDO) to cysteinesulfinate, which is decarboxylated by 
cysteinesulfinic acid decarboxylase (CSAD) to hypotaurine. The other pathway involves the 
conversion of cysteine to Coenzyme A, which releases cysteamine during degradation. 
Cysteamine is then oxidized to hypotaurine via cysteamine dioxygenase (ADO). In both 
pathways, hypotaurine is subsequently oxidized to taurine. Taurine has been shown to be 
beneficial to intestinal function; however, little is known regarding taurine biosynthesis in the 
intestine. Recent studies have localized the expression of CDO in rodent intestine to goblet cells, 
suggesting they may be able to synthesize taurine. To determine whether the pathways for 
taurine biosynthesis are present in intestinal goblet cells, we measured ADO, CDO, and CSAD 
mRNA as well as hypotaurine and taurine levels in LS174T cells in response to cysteine and 
cysteamine. In addition, we examined the same end points in response to different inflammatory 
triggers, namely bacterial flagellin, IL-13, and TNFα to determine whether they might induce 
taurine biosynthesis. ADO, CDO, and CSAD were all detected at the mRNA level in the LS174T 
cell line, suggesting that these cells could have the capacity to synthesize taurine via both 
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pathways. Increased intra- and extracellular hypotaurine and intracellular taurine levels were 
observed in response to cysteamine treatment, indicating that LS174T cells can synthesize 
hypotaurine/taurine from cysteamine via the ADO pathway. This was not associated with an 
increase in ADO mRNA levels. Intracellular taurine was increased in response to cysteine, which 
suggested taurine synthesis via the CDO/CSAD pathway but needs to be confirmed by additional 
studies. Flagellin, IL-13, and TNFα treatments differentially upregulated gene expression of 
taurine biosynthetic enzymes. IL-13 increased intracellular taurine levels but did not increase 
taurine export at the times and concentrations examined. TNFα appeared to increase hypotaurine 
and taurine synthesis and export, while flagellin primarily increased taurine and hypotaurine 
export. Overall, these results demonstrate that LS174T cells synthesize taurine and that taurine 
synthesis and transport is modulated by certain inflammatory signals.  
 
INTRODUCTION 
Taurine (2-aminoethanesulfonate) is one of the most abundant free amino acids present in 
the body [1, 2]. It can be obtained exogenously from the diet or be synthesized in the body from 
cysteine [1, 2]. Taurine has a number of cytoprotective properties, including antioxidant, anti-
inflammatory, osmoregulatory, and membrane stabilizing effects [1, 2]. Taurine’s precursor, 
hypotaurine, can also serve as an antioxidant [2]. 
Recent studies have revealed taurine supplementation to be beneficial in rodent models of 
inflammatory bowel disease due to its anti-inflammatory and antioxidant properties. Taurine 
supplementation was demonstrated to ameliorate inflammatory parameters in trinitrobenzene 
sulfonic acid (TNBS)-induced inflammatory bowel disease in rats possibly by decreasing 
inflammatory reactions, oxidative damage, and apoptosis [3, 4]. Furthermore, use of 5-
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aminosalicyltaurine as a colon-specific pro-drug of 5-aminosalicylic acid (5-ASA), which is 
cleaved into taurine and 5-ASA in cecal contents [5], showed enhanced anti-inflammatory 
effects compared to 5-ASA alone in TNBS-induced colitis in rats [6], again suggesting an anti-
inflammatory role for taurine in the colon. Likewise, taurine supplementation diminished disease 
severity and inflammatory response in dextran sulfate sodium (DSS)-induced colitis in mice [7, 
8]. In vitro studies using human intestinal epithelial Caco-2 cells showed that taurine could 
inhibit TNFα induced IL-8 secretion and mRNA expression [8]. Taurine is absorbed across the 
apical membrane in the intestine by two transporters, TauT and PAT1 [9]. TNFα was found to 
increase taurine uptake by Caco-2 cells, which was associated with an increase in TauT mRNA 
levels and affinity [10]. Thus, current evidence suggests that taurine is beneficial against 
inflammation and that intestinal epithelial cells increase taurine uptake in response to 
inflammatory signals. However, the ability of intestinal epithelial cells to synthesize taurine 
under normal conditions and in response to inflammation remains unknown. 
In mammals, there are two pathways for taurine synthesis (Figure 5.1). One is via 
oxidation of cysteine to cysteinesulfinate (CSA) by cysteine dioxygenase (CDO; EC1.13.11.20), 
followed by decarboxylation of CSA to hypotaurine by cysteinesulfinic acid decarboxylase 
(CSAD; EC4.1.1.29), and finally the oxidation of hypotaurine to taurine by a poorly understood 
mechanism [11]. The other pathway begins with the incorporation of cysteine into Coenzyme A 
(CoA), followed by the release of cysteamine during CoA degradation, the oxidation of 
cysteamine to hypotaurine and finally the oxidation of hypotaurine to taurine [12]. CDO is 
expressed in both a tissue- and cell-specific manner and is especially abundant in the liver, while 
ADO is expressed more ubiquitously [12-15]. CSAD expression tends to be high in tissues 
expressing high levels of CDO [14]. There have been no published descriptions of ADO 
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expression within the small intestine or colon. However, CDO was previously demonstrated to 
be expressed in mouse small intestine and colon at the protein level and appeared to localize to 
goblet cells in rat small intestine [14, 16]. In Chapter 4, we showed that CDO localized to goblet 
cells in mouse small intestine, colon, and cecum, as well as the other two cell types of the 
secretory lineage, enteroendocrine and Paneth cells. One possible reason for CDO localization to 
intestinal goblet cells is to allow for taurine biosynthesis. In fact, taurine was demonstrated to 
localize to mucus granules in goblet cells in mouse intestine [17]. CSAD was also shown to be 
expressed in mouse colon at the protein level, but was not detected in mouse duodenum [14]. 
The inability to detect CSAD in mouse duodenum, however, might have been due to the use of 
whole tissue homogenates of which the secretory lineage would comprise a limited portion in the 
small intestine.  
To understand more about taurine biosynthesis in intestinal goblet cells we examined 
ADO, CDO, and CSAD mRNA and taurine and hypotaurine levels in response to cysteine and 
cysteamine in LS174T cells, a human adenocarcinoma cell line which expresses a goblet cell like 
phenotype. Because of the potential anti-inflammatory role of taurine in the intestine, we also 
sought to determine whether intestinal goblet cells would be induced to produce more taurine in 
response to different inflammatory triggers, namely bacterial flagellin, IL-13, and TNFα. 
 
MATERIALS AND METHODS 
Reagents. Bathocuproine disulfonic acid (BCS), cysteamine hydrochloride, hypotaurine, 
glutathione ethyl ester (GSHee), taurine, and 2-aminoethyl hydrogen sulfate (2-AEHS) were 
purchased from Sigma. L-cysteine free base was purchased from MP Biomedicals. Recombinant 
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human IL-13 and TNFα were purchased from PeproTech. Recombinant Flagellin from S. 
typhimurium was purchased from InvivoGen. 
 
Cell Culture. The human LS174T colorectal cancer cell line was obtained from the American 
Type Culture Collection (ATCC). LS174T cells were maintained in Minimum Essential Medium 
(MEM) supplemented with 10% Fetalplex (Gemini Biosciences), 1.5g/L of Na2CO3, 50 units/mL 
penicillin G and 50 mg/mL streptomycin sulfate at 37°C in 5% CO2. To examine the effects of 
cysteine and cysteamine, cells were seeded into 12-well plates at a density of 4 x 105 cells/well. 
After approximately 48 h, cells were washed twice with 1X HBSS and fresh maintenance media 
containing 40 µM bathocuproine disulfonic acid + 1 mM cysteine or 1 mM cysteamine was 
added. After 48 h, conditioned media were collected and cells were harvested for RNA isolation. 
For experiments examining effects of flagellin, IL-13, and TNFα, cells were seeded into 24-well 
plates at a density of 2 x 105 cells/well. After approximately 48 h, cells were washed twice with 
1X HBSS and fresh antibiotic-free maintenance media containing different concentrations of 
flagellin, IL-13, or TNFα were added to the cells. After 24 h, conditioned media were collected 
and cells were harvested for RNA isolation. 
 
Quantitative RT-PCR. Total RNA was isolated from cells using the RNeasy Plus Kit (Qiagen) 
according to the manufacturer’s instructions for animal cells. The quality and quantity of RNA 
isolates were determined by Nanodrop (Thermo Fisher Scientific). RNA isolates were reverse 
transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied Biosystems) 
according to the manufacturer’s instructions. Quantitative real-time PCR was performed using 
SYBR Green PCR Master Mix (Applied Biosystems) and the primers described in Table 5.1 and 
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Table 3.1. Reactions were run in triplicate in a 384-well plate using an Applied Biosystems 
7900HT Fast Real-Time PCR System. Final quantifications were performed using the standard 
curve method with the geometric mean of GAPDH and RPLP0 used for normalization. No 
reverse transcription reactions were performed to confirm the specificity of the reactions for 
RNA.  
 
LC/MS/MS Measurement of Cysteine, Cystine, Hypotaurine, and Taurine in Cysteine- and 
Cysteamine-treated samples. Cysteine, cystine, hypotaurine, and taurine were measured in 
conditioned media (extracellular) and cellular lysates (intracellular) using LC/MS/MS. 
Conditioned media was collected mixed with internal standards glutathione ethyl ester (GSHee) 
and 2-aminoethyl hydrogen sulfate (2-AEHS) and diluted into 5 mM iodoacetic acid (IAA) in 5 
mM ammonium bicarbonate. After collection of conditioned media, cells were washed once in 
1X HBSS, harvested using 1X trypsin/EDTA, and washed in 1X PBS. Cells were resuspended in 
10 mM IAA in 10 mM ammonium bicarbonate and were lysed by 3 cycles of freezing and-
thawing. Lysates were centrifuged at 13,000 rpm for 2 min. The supernatant fraction was 
collected, mixed with internal standards GSHee and 2-AEHS, and diluted for a final IAA 
concentration of 5 mM. Reactions with IAA were allowed to proceed for 15 minutes at room 
temperature. Samples were stored at -80oC until analyzed using an ABI 5500 QTrap MS with 
Agilent 1200 LC. Values for cysteine, cystine, hypotaurine, and taurine were calculated using 
external calibration. The total protein content of the cellular lysates was measured using the 
Reducing Agent Compatible BCA Protein Assay kit (Pierce). Intracellular values for cysteine, 
cystine, hypotaurine, and taurine were normalized to lysate protein concentration. 
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LC/MS/MS Measurement of Hypotaurine and Taurine in Flagellin-, IL-13-, and TNFα−treated 
samples. Hypotaurine, and taurine were measured in conditioned media (extracellular) and 
cellular lysates (intracellular) using LC/MS/MS. Conditioned media were collected, mixed with 
internal standard 2-AEHS and diluted into nanopure water. After collection of conditioned 
media, cells were washed once in 1X HBSS, harvested using 1X trypsin/EDTA, and washed in 
1X PBS. Cells were resuspended in nanopure water and were lysed by 3 cycles of freezing and-
thawing. Lysates were centrifuged at 13,000 rpm for 2 min. The supernatant fraction was 
collected, mixed with 2-AEHS, and diluted with nanopure water to match volumes of 
hypotaurine and taurine standards and conditioned media samples. Samples were stored at -80oC 
until analyzed using an ABI 5500 QTrap MS with Agilent 1200 LC. Values for hypotaurine and 
taurine were calculated using external calibration. The total protein content of the cellular lysates 
was measured using the Reducing Agent Compatible BCA Protein Assay kit (Pierce). 
Intracellular values for hypotaurine and taurine were normalized to lysate protein concentration. 
 
Statistical Analysis. ANOVA and Fisher's protected least significant difference test (FLSD test) 
were used to compare differences. These analyses were carried out using SAS software 
(Statview, Version 5.0.1; SAS Institute, Cary, NC). Differences were considered significant at p 
< 0.05. 
 
RESULTS 
Expression of ADO, CDO, and CSAD in LS174T Cells and Validation of Primers for 
Quantitative RT-PCR. Primers for ADO, CDO, and CSAD produced a single amplicon (Figure 
5.2A) of expected size (Table 5.1) by conventional RT-PCR and a single peak upon dissociation 
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curve analysis following quantitative RT-PCR (Figures 5.2B). These results confirmed the 
expression of ADO, CDO and CSAD at the mRNA level in LS174T cells. Quantitative RT-PCR 
also revealed CDO expression to be much lower in LS174T cells than in human liver RNA (data 
not shown). Primers for CSAD were found to produce multiple bands when used with human 
liver RNA (data not shown). 
 
ADO, CDO, and CSAD Expression in Response to Cysteine and Cysteamine. Changes in ADO, 
CDO, and CSAD were examined at the mRNA level using quantitative RT-PCR to determine 
whether there were any transcriptional changes in response to cysteine or cysteamine treatment. 
Expression of ADO was found to be slightly decreased by cysteamine, but unaltered by cysteine 
(Figure 5.3). CSAD gene expression remained unchanged by cysteamine or cysteine, and CDO 
expression was only minimally downregulated by cysteine.  
 
MUC2, RETNLB, and TFF3 Expression in Response to Cysteine and Cysteamine. Quantitative 
RT-PCR for MUC2, RETNLB, and TFF3 was performed to determine whether treatment of 
LS174T with cysteine and cysteamine affected transcription of the cysteine-rich goblet cell 
secretory products. As shown in Figure 5.4, there was no change in MUC2 or TFF3 expression 
in response to cysteine or cysteamine, but RETNLB expression was increased approximately 2-
fold in response to cysteamine. 
 
Hypotaurine/Taurine Biosynthesis in LS174T Cells from Cysteamine and Cysteine. Hypotaurine 
is formed as a product of cysteine catabolism by CDO plus CSAD or as a product of cysteamine 
catabolism by ADO. Hypotaurine is further oxidized to taurine by a still unknown mechanism. 
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Hypotaurine and taurine can be transported out of cells, so to assess the ability of LS174T cells 
to synthesize hypotaurine and taurine from cysteamine and cysteine, we measured both 
intracellular and extracellular levels using LC/MS/MS. We also measured intracellular cysteine 
and cystine. Two independent experiments were performed. However, in the case of cysteine, 
levels were found to be nearly 5X higher in the second experiment compared to the first 
experiment (Figure 5.5A and B). Consequently, the two experiments were analyzed separately 
and it was observed in each that intracellular cysteine concentrations were increased in cells 
grown in media with 1 mmol/L cysteine added. Values for intracellular cystine were relatively 
similar between experiments and, when analyzed together, cystine was observed to be more than 
5 times greater in cells grown with added cysteine (Figure 5.5C). Both intracellular and 
extracellular hypotaurine levels were significantly increased in response to addition of 
cysteamine to the media, but remained unchanged with cysteine (Figure 5.6). A moderate 
increase in intracellular taurine levels occurred in response to both cysteamine and cysteine, but 
extracelluar taurine was unaltered by cysteamine and somewhat decreased by cysteine. 
 
Hypotaurine/Taurine Biosynthesis in Response to Flagellin, IL-13, and TNFα. To determine 
whether inflammatory signals might stimulate goblet cells to increase taurine biosynthesis, 
changes in ADO, CDO, and CSAD expression at the mRNA level and intra- and extracellular 
hypotaurine and taurine were measured in response to treatment with flagellin, IL-13, and TNFα 
for 24 h. Exposure to flagellin led to a slight increase in ADO expression at 500 ng/mL and about 
a 3.5-fold increase in CSAD expression at 1000 ng/mL (Figure 5.7). Expression of CDO was not 
significantly changed by treatment with flagellin. Intra- and extracellular hypotaurine and taurine 
levels were only examined in response to 500 ng/mL and 1000 ng/mL concentrations of flagellin 
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since only those concentrations seemed to modulate gene expression and had been previously 
shown to induce IL-8 secretion from LS174T cells (see Chapter 3). Intracellular hypotaurine and 
taurine were decreased in response to 1000 ng/mL of flagellin (Figures 5.8A and 5.9A), but 
extracellular levels of hypotaurine and taurine were elevated (Figures 5.8B and 5.9B). The 
increases in extracellular hypotaurine and taurine following exposure to 1000 ng/mL of flagellin 
for 24 h are consistent with a previous experiment (data not shown). IL-13 enhanced expression 
of ADO, CSAD, and CDO, with CSAD expression being the most affected of the three in terms of 
relative fold change (Figure 5.7). Because 5 ng/mL and 10 ng/mL of IL-13 seemed to have the 
greatest influence on CSAD and CDO expression, these concentrations were used to analyze 
hypotaurine and taurine biosynthesis in response to IL-13. Intracellular taurine concentrations 
were higher with 5 ng/mL of IL-13, but intracellular hypotaurine was unchanged with either 
concentration (Figures 5.8A and 5.9A). Both extracellular hypotaurine and taurine appeared to 
be slightly elevated in response to IL-13, but this did not reach statistical significance (Figures 
5.8B and 5.9B). However, in a previous study, IL-13 treatment at concentrations of 5 ng/mL and 
10 ng/mL resulted in statistically significant increases in extracellular hypotaurine and taurine. 
TNFα produced a less than 2-fold increase in ADO expression and a 2 to 2.5-fold increase in 
CDO expression (Figure 5.7). Of the three taurine biosynthetic enzymes, expression of CSAD 
was most affected by TNFα being increased more than 3-fold. Intracellular hypotaurine and 
taurine were not changed by TNFα (Figures 5.8A and 5.9A), while extracellular hypotaurine 
and taurine were both increased with 10-1000 ng/mL of TNFα (Figures 5.8B and 5.9B). 
Increased extracellular hypotaurine with 1000 ng/mL of TNFα and taurine with 100-1000 ng/mL 
of TNFα were also observed in previous experiment (data not shown). 
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DISCUSSION 
 Recent in vivo and in vitro studies indicate taurine can help attenuate inflammation 
associated with inflammatory bowel disease [3, 4, 6-8, 10]. These studies have focused on 
exogenous provision of taurine, but our recent finding that CDO is expressed in the secretory 
lineage of mouse small intestine and colon suggests that intestinal epithelial cells may have the 
capacity to synthesize taurine. In this study we focused on intestinal goblet cells, using the 
human adenocarcinoma LS174T cell line, which expresses a goblet cell-like phenotype. We 
observed that this cell line expresses ADO, CDO, and CSAD at the mRNA level, indicating that 
these cells may be able to synthesize taurine via both the CDO/CSAD and the ADO pathway. 
The increase in intra- and extracellular hypotaurine and intracellular taurine in response to 
cysteamine confirmed that LS174T cells are capable of synthesizing hypotaurine/taurine via the 
ADO pathway. This was not associated with an increase in ADO mRNA levels, consistent with 
studies conducted in adipocytes where ADO mRNA and protein levels were also unchanged in 
response to cysteamine [18]. Thus, the increased hypotaurine production was likely due to 
increased substrate for ADO. The incomplete oxidation of hypotaurine to taurine may indicate 
that the cells have limited capacity to oxidize hypotaurine to taurine. 
Intracellular taurine was increased in response to cysteine, but intra- and extracellular 
hypotaurine were unaltered and extracellular taurine was decreased. The increase in intracellular 
taurine could have resulted from increased synthesis via the CDO/CSAD pathway. The increased 
intraceullar taurine in response to cysteine was not associated with an increase in ADO, CDO, or 
CSAD mRNA expression. The unresponsiveness of ADO and CSAD to cysteine at the mRNA 
level was expected based on previous studies [12, 18, 19]. CDO is not typically regulated in 
response to cysteine at the mRNA level or protein level in non-hepatic tissues, with the apparent 
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exception of adipose tissue [18, 19]. In liver, CDO is also not regulated at the mRNA level, but 
protein abundance increases in response to cysteine. Thus, additional studies should be done to 
determine whether CDO protein abundance is increased in LS174T cells in response to cysteine. 
This additional data plus confirmation of CSAD expression at the protein level would help 
validate that cysteine is increasing intracellular taurine via the CDO/CSAD pathway. 
Alternatively, since extracellular taurine levels were decreased in response to cysteine, 
intracellular taurine levels may have been elevated due to taurine transport into the cells rather 
than additional synthesis. Perhaps the elevated intracellular cysteine and cystine levels observed 
with addition of 1 mmol/L of cysteine altered the intracellular redox potential, stimulating cells 
to take up extracellular taurine in order to maintain redox homeostasis.  
 Because of taurine’s reported anti-inflammatory effects, we examined whether selected 
inflammatory stimuli, namely flagellin, IL-13, and TNFα, could induce taurine biosynthesis in 
LS174T cells and alter ADO, CDO, and CSAD abundance at the mRNA level. Flagellin 
upregulated CSAD expression, indicating possible stimulation of taurine biosynthesis via the 
CDO/CSAD pathway. However, the decreased intracellular hypotaurine and taurine levels and 
increased extracellular levels of hypotaurine and taurine following treatment with flagellin, 
suggest that hypotaurine and taurine are exported from cells in response to flagellin before or 
faster than additional hypotaurine and taurine can be synthesized. The upregulation of ADO, 
CDO, and CSAD expression and increase in intracellular taurine by IL-13 treatments indicates 
that cells may increase taurine biosynthesis via both taurine biosynthetic pathways. TNFα 
similarly increased ADO, CDO, and CSAD expression, but since a greater fold change was 
observed with CDO and CSAD than ADO, the CSAD/CDO pathway may play a more significant 
role in taurine biosynthesis in response to TNFα. Thus, TNFα likely induces cells to synthesize 
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and export hypotaurine/taurine. Contrary to our findings, another study examined the effects of 
TNFα and TGFβ on CDO expression in human neuronal and hepatic cell lines and observed a 
decrease in CDO expression [20]. This could indicate that responses of taurine biosynthetic 
enzymes to cytokines are cell type-specific.  
Overall our results indicate that IL-13 and ΤΝFα increase hypotaurine/taurine 
biosynthesis in part by increased gene expression of taurine biosynthetic enzymes and that both 
flagellin and ΤΝFα stimulate cells to export hypotaurine/taurine extracellularly. Additional 
studies should be conducted to determine whether extended treatment with IL-13 also results in 
export of hypotaurine and taurine and whether extended treatments with flagellin and ΤΝFα 
eventually lead to increased intracellular hypotaurine and taurine. Since CDO is primarily 
regulated at the protein level in liver, it would be interesting to determine whether the 
inflammatory stimuli found to increase CDO gene expression in this study also increase CDO 
protein abundance.  
It is interesting that the LS174T cell line appears to export taurine in response to two 
inflammatory stimuli, flagellin and ΤΝFα, rather than taking up taurine as had been observed in 
Caco-2 cells in response to ΤΝFα and IL-1β [10]. The phenotype of Caco-2 cells is more similar 
to that of an enterocyte while the phenotype of LS174T cells is more similar to that of a goblet 
cell. Thus, the observed difference in taurine transport between these cell lines may reflect 
differences in taurine handling between enterocytes and goblet cells. This would be consistent 
with our observation of CDO being expressed in goblet cells but not enterocytes. Since Paneth 
cells and enteroendocrine cells were also observed to express CDO in mouse, it would be 
interesting to see whether these two secretory cell types respond similarly to goblet cells when 
treated with inflammatory stimuli.  
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Taurine synthesized and exported from intestinal goblet cell in response to inflammation 
may provide an endogenous source of taurine for enterocytes to use to counteract inflammation 
as well as a source of taurine to react with hypochlorous acid, which is produced by 
myeloperoxidase in activated leukocytes, and forms taurine chloramines [21]. Taurine 
chloramine exhibits strong anti-inflammatory activity by downregulating nuclear factor-κb (NF-
κB) activity and proinflammatory products including prostaglandins, nitric oxide, and cytokines 
[22, 23]. This is considered to be the major mechanism by which taurine potentiates the effect of 
5-ASA in TNBS-induced colitis [24]. Further studies should be conducted to determine whether 
goblet cells provide taurine for use by other cells in situ. 
 In summary, we demonstrated that the LS174T cell line expresses ADO, CDO, and 
CSAD at the mRNA level. LS174T cells were able to synthesize hypotaurine/taurine via the 
ADO pathway starting with cysteamine and possibly the CDO/CSAD pathway starting with 
cysteine. However, additional studies are required to confirm the use of the CDO/CSAD 
pathway. Flagellin, IL-13, and ΤΝFα can induce taurine biosynthesis and/or export from 
LS174T cells, and increased taurine biosynthesis appears to involve enhanced expression of 
genes encoding taurine biosynthetic enzymes in response to these inflammatory stimuli. 
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Chapter 6 
FUTURE DIRECTIONS 
 
In Chapter 2, interindividual and regional differences in sulfomucins and sialomucins 
were quantified in the right colon, left colon, and rectum of healthy individuals. While the 
approach used for quantitative analysis yielded important information regarding sulfo- and 
sialomucin abundance in the human colon, the method was found to be time consuming and 
somewhat subjective due to issues with the selection of the pixel color in the Automeasure 
module. There are also some inherent issues with the high iron diamine and alcian blue 
(HID/AB) stain that was used to distinguish sulfomucins and sialomucins, including masking of 
the presence of sialomucin by the HID stain and the potential for the HID stain to react non-
specifically with other anionic groups [1]. Furthermore, the HID/AB staining cannot provide 
detailed information about which sugar groups are sulfated or sialylated or how many sulfate or 
sialic acid groups are present. To eliminate some of these issues, current work is in progress to 
develop a Fourier Transform Infrared (FTIR) spectroscopy imaging based approach to analyze 
sulfomucins and sialomucins in human intestinal biopsies. FTIR spectroscopic imaging 
combines the molecular selectivity of spectroscopy with the spatial specificity of optical 
microscopy [2]. Once algorithms are developed to classify sulfomucins and sialomucins, FTIR 
imaging will allow us to quantify these mucin chemotypes in unstained biopsy sections based on 
their chemical composition. Since the process is fully automated and eliminates the need for 
staining, it is much less time consuming than the image analysis technique used for mucin 
quantification in Chapter 2. FTIR imaging is also a much more objective way to analyze tissues 
since it eliminates the need for interpretation of staining. With the development of this technique 
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it may also be possible to analyze mucin composition in much more detail than can be performed 
with current staining protocols. Having this detail would be very useful in providing a deeper 
understanding of mucin-microbe associations.  
It was reported in Chapter 2 that female subjects in our study on average exhibited 
greater sialomucin abundance in the rectum than male subjects and noted that additional studies 
should be completed to determine whether this finding would hold true for a larger number of 
subjects. More information is also needed regarding the influence of other demographic variables 
on mucin chemotypes, because normal values may vary between different groups of individuals 
depending on race, ethnicity, age, etc., and this information may help identify why certain 
populations are more susceptible to gastrointestinal disease than others. Associations between 
mucin chemotypes and diet in humans could also provide useful information. Animal models 
have demonstrated that mucin composition can be altered by diet [3-8]. By distinguishing 
individuals by diet and examining both mucin chemotypes and microbes, the high interindividual 
variation observed in SRB profiles might be reduced within dietary groups, and thereby enable 
the identification of associations between mucin chemotypes and SRB.  
 Changes in sulfo- and sialomucin have been previously described in association with 
ulcerative colitis (UC) and colorectal adenocarcinomas, but have been examined to a much lesser 
extent in Crohn’s disease (CD). Furthermore, whether changes in mucin chemotype are 
associated with altered microbiota in human gastrointestinal disease has not been fully examined. 
A study is currently in progress to study sulfo- and sialomucins and microbial profiles in ileal 
and colonic biopsies collected from healthy subjects and inflamed and adjacent normal tissue in 
patients with CD and UC. As shown in Figure 6.1, we have already observed an increase in 
sialomucins associated with inflamed regions in a subject with CD. Once we have finished 
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analyzing mucins and microbial profiles in these subjects, we can use multivariate analysis as 
was done in Chapter 2 to determine the extent to which subjects cluster based on disease severity 
or whether only samples from actively inflamed regions cluster together.  
In Chapter 3, an in vitro model of human colonic goblet cells was used to determine 
factors that might contribute to differences in sulfomucin abundance and the loss of mucin 
sulfation previously described in both inflammatory bowel disease and colonic adenocarcinomas. 
We determined that both host and microbial factors could enhance sulfomucin production 
possibly via upregulation of mucin sulfotransferases. A major component missing from this 
study, however, was analysis of secreted sulfomucin. This is important as treatments could be 
inducing additional sulfomucin to be secreted from the cells, which could make it appear that 
sulfomucin synthesis has not been altered. Several treatment time points should also be examined 
to better understand the dynamics of how long it takes for an increase in sulfotransferase 
expression to result in increased sulfomucin synthesis and secretion. Additional studies are also 
needed to determine the mechanisms by which microbial and host factors modulate expression of 
sulfotransferases. For example, it needs to be determined whether flagellin induces mucin 
sulfotransferases via interaction with TLR5 and downstream signaling or via another mechanism. 
The findings from Chapter 3 should also be examined in non-transformed cells to ascertain 
whether they are specific to the LS174T cell line or are reflective of the normal response of 
intestinal goblet cells. Finally, if protocols could be developed to examine mucin sulfation in 
goblet cells using primary cell culture, one could explore whether goblet cells from subjects with 
active IBD exhibit the same mucin sulfation responses as in normal subjects.  
 As described in Chapter 4, expression of cysteine dioxygenase (CDO), an important 
enzyme in cysteine catabolism, was demonstrated to be restricted to cells of the secretory but not 
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the absorptive lineage in the small intestine, colon, and cecum. CDO may also be expressed by 
intestinal stem cells. Studies are underway to determine whether CDO colocalizes with intestinal 
stem cell markers, leucine-rich repeat-containing G-protein-coupled receptor (LGR5), a marker 
for rapidly cycling intestinal stem cells, and doublecortin and CaM kinase-like-1 (DCAMKL-1), 
a marker for quiescent intestinal stem cells [9]. Additional studies are also needed to determine 
whether the cell type-specific expression of CDO in the intestine is consistent among species. 
Finally, recent staining for CDO performed in CDO knockout mice revealed positive CDO 
staining (see Appendix B), so whether the CDO antibody is actually staining CDO or cross-
reacting with another protein needs to be resolved.  
 Taurine is one possible end product of cysteine catabolism by CDO. Consequently, as 
described in Chapter 5, we examined taurine biosynthesis in LS174T cells, a human goblet-cell 
like line via the two pathways of taurine biosynthesis. It was demonstrated that LS174T cells 
synthesize taurine via the ADO pathway but that synthesis of taurine via the CDO/CSAD 
pathway was equivocal. The first issue that should be addressed in this regard is whether CDO 
and CSAD are expressed at the protein level in LS174T cells. Then, it should be determined if 
CDO and/or CSAD protein abundance and activity are increased in response to cysteine. In 3T3-
L1 cells, CDO, CSAD, and ADO protein levels increased during adipogenic differentiation and 
this was accompanied by changes in hypotaurine and taurine production [10]. Additional 
experiments could be performed using the HT29-Cl.16E cell line, which differentiates into 
goblet cells, to examine whether the differentiation state affects taurine biosynthesis and 
expression of taurine biosynthetic enzymes. We also observed that flagellin, IL-13, and TNFα 
modulated gene expression of taurine biosynthetic enzymes as well as taurine biosynthesis 
and/or taurine export from the cells. Further studies should be completed to determine whether 
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protein abundance of taurine biosynthetic enzymes is increased in response to flagellin, IL-13, 
and TNFα and whether longer treatment times result in higher hypotaurine and taurine levels. 
Since cysteine is involved in the synthesis of other products that could offer protection during 
inflammation, such as glutathione, goblet cell secretory products, and sulfate [11], which, in turn, 
could be used for sulfomucin synthesis, it would be interesting to measure these products in 
addition to taurine to determine whether cysteine might be preferentially used to synthesize 
certain products over others both under normal conditions and in response to inflammation. One 
could also examine whether provision of additional cysteine or cysteamine would allow cells to 
enhance synthesis of any of these products and thereby offer additional protection against 
inflammation. Such experiments would contribute to a much needed understanding of cysteine 
metabolism in intestinal goblet cells. Finally, the results of these studies should be examined in 
an animal model or using primary cell culture to determine whether these findings are applicable 
to normal intestinal goblet cells or specific to the LS174T cell line.  
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APPENDIX A 
ADDITIONAL EXPERIMENTS EXAMINING EFFECTS OF MICROBIAL COMPONENTS, 
IL-13, and HYDROGEN SULFIDE ON GOBLET CELLS 
 
A.1 Lipopolysaccharide (LPS) and Pam3CSK4 
The responsiveness of goblet cells to known TLR4 agonist LPS, and synthetic TLR 1/2 
agonist (Pam3CSK4) was examined in the LS174T cell line. LPS from E. coli O111:B5 was 
provided by Dr. Richard Tapping and Pam3CSK4 was purchased from Invivogen. LS174T cells 
were cultured for 6 h and 24 h in medium containing different concentrations of Pam3CSK4 or 
LPS, after which the conditioned media and cells were collected. RNA was isolated from the 
cells, and CDX2, MUC2, RETNLB, and TFF3 expression was examined using quantitative RT-
PCR. The data were normalized to GAPDH and RPLP0 expression. IL-8 secretion was also 
measured using an ELISA (R & D Systems) to determine whether the cells were responding to 
the treatments. Comparisons were performed using SAS software (Statview, Version 5.0.1; SAS 
Institute, Cary, NC). ANOVA and Fisher's protected least significant difference test were used to 
compare differences with an assigned p-value of < 0.05.  
As shown in Figure A.1, significant changes were not observed upon treatment with LPS 
for 6 h, and only about a 25% decrease in MUC2 and 30% decrease TFF3 expression occurred 
after 24 h of treatment with the highest concentration of LPS. Secretion of IL-8 was measured in 
the conditioned media of cells treated for 24 h. A statistically significant decrease in IL-8 
secretion occurred with the 1 μg/mL LPS treatment (Figure A.2). However, because it was only 
a 7% decrease compared to the untreated secretion of IL-8 with a p-value of 0.045, it is possible 
that this result is not a biologically significant difference. Thus, both the gene expression data 
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and IL-8 secretion data indicate that, overall, the cells were unresponsive to LPS. The limited 
response to LPS might be the result of insufficient expression of TLR4 by the cells. 
Treatment with 10 ng/mL of Pam3CSK4 for 6 h resulted in a statistically significant, but 
small, increase in MUC2 (1.3-fold) and RETNLB (1.5-fold) expression and decrease in TFF3 
(1.2-fold) expression (Figure A.3). At 24 h, a decrease in RETNLB (1.4-fold) was observed with 
1 μg/mL of Pam3CSK4 and MUC2 (1.3-fold) with all concentrations of Pam3CSK4. Expression 
of CDX2 and TFF3 was unaltered for all concentrations examined for 24 h. Since the goblet cell 
secretory product genes seemed to be somewhat responsive to Pam3CSK4, we proceeded to 
determine whether expression of the mucin sulfotransferase genes, CHST5 and GAL3ST2, was 
altered by treatment with Pam3CSK4. At 6 h, an increase in both CHST5 (1.4-fold) and GAL3ST 
(1.8-fold) was observed with 10 ng/mL of Pam3CSK4 (Figure A.4). After 24 h of treatment with 
Pam3CSK4, GAL3ST2 expression did not differ significantly from the control, and CHST5 was 
downregulated about 1.6-fold with 1 μg/mL of Pam3CSK4. IL-8 secretion was also measured 
from cells treated with Pam3CSK4. As shown in Figure A.2, a statistically significant decrease 
in IL-8 secretion occurred with the 1 μg/mL Pam3CSK4 treatment for 24 h. However, this only 
amounted to a 1.1-fold decrease with a p-value of 0.048, and when the treatment was repeated 
(Figure A.5) a significant difference was not observed. One possible explanation for the lack of 
IL-8 secretion by the cells in response to Pam3CSK4 is the chosen treatment times and 
concentrations. Other studies reported increased IL-8 secretion from the T84 intestinal epithelial 
cell line using 50 μg/mL of Pam3CSK 4 [1, 2], so we tested whether the LS174T cell line would 
secrete IL-8 in response to this higher concentration of Pam3CSK4. Treatments with TNFα and 
flagellin (S. tymphimurium) were performed as controls. Cells were incubated for 24 h with the 
treatments indicated in Figure A.5. Cells and conditioned media were collected for analysis of 
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gene expression and IL-8 secretion, respectively. Treatment with TNFα resulted in a 5-fold 
increase in IL-8 secretion and 500 ng/mL of flagellin produced a 3.5-fold increase, but none of 
the other treatments significantly altered secretion of IL-8. Podolsky et al. described an increase 
in TFF3 mRNA in LS174T cells after 30 minutes of treatment with 20 µg/mL of Pam3CSK4 and 
an increase in TFF3 secretion after 24 h of treatment with 20 µg/mL of Pam3CSK4 [3]. They did 
not mention whether IL-8 secretion was examined. Thus, it may be that Pam3CSK4 is able to 
initiate TFF3 transcription and secretion without inducing IL-8 secretion. Furthermore, early 
time points may need to be examined to detect changes in TFF3 expression in response to certain 
stimuli. 
 
A.2 IL-13 effects on pre- and post-confluent HT29CL.16E cells 
The ability of IL-13 to modulate sulfated and sialylated mucins and the sulfotransferase genes, 
CHST5 and GAL3ST2, at different stages of goblet cell differentiation was examined using 
HT29CL.16E cells, which differentiate to have a goblet cell-like phenotype in early post-
confluence, at pre-confluen and 5 days post-confluence. re-confluent cells and 5 days post-
confluent cells were treated with 1 ng/mL IL-13 (purchased from Sigma) for 24 h. Gene 
expression was evaluated using quantitative RT-PCR. Sialylated and sulfated mucin content was 
assessed by staining with HID/AB. Similar to results reported with the LS174T cell line in 
Chapter 3, CHST5 expression increased in HT29CL.16E cells treated with IL-13 (Figure A.6). 
However, in this cell line the less differentiated pre-confluent cells were more responsive to IL-
13, in terms of CHST5 upregulation, than the more differentiated post-confluent cells. There was 
no detectable expression of GAL3ST2 in IL-13 treated or untreated HT29CL.16E cells at either 
stage of differentiation. This corroborates previous data showing that certain oligosaccharides 
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isolated from HT29CL.16E cells contain a sulfate residue linked in position C-6 of a galactose 
residue [4]. Staining of pre- and post-confluent HT29Cl.16E cells revealed what appeared to be 
an increase in HID staining, and thus sulfomucin production (Figures A.7 and A.8). However, 
additional analyses of mucins should be done to confirm this finding. Overall, it appears that IL-
13 can induce mucin sulfation, possibly via the sulfotransferase CHST5 in the HT29Cl.16E cell 
line, which is in accord with the results reported with the LS174T cell line in Chapter 3. 
Furthermore, goblet cells that are more differentiated may be less responsive to IL-13 
modulation. Thus, relative position along the crypt could affect how goblet cells respond to 
inflammatory stimuli. 
 
A.4 Sulfide  
The effects of sulfide on CHST5 and GAL3ST2 gene expression were investigated using the 
LS174T cell line. Cells were treated with sodium sulfide for 6 h and 24 h and then harvested for 
RNA isolation. Gene expression for CHST5 and GAL3ST2 was evaluated using quantitative RT-
PCR and normalized to expression of RPLP0. As shown in Figure A.9, sulfide did not 
significantly alter expression of either sulfotransferase after 6 h of treatment. However, after 24 h 
of treatment with sulfide, CHST5 expression was increased more than 4-fold and GAL3ST2 
expression was increased approximately two-fold. Thus, sulfide may stimulate goblet cells to 
produce more sulfomucins. 
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APPENDIX B 
CDO KNOCKOUT MICE 
 
INTRODUCTION 
The aim of this study was to better understand the functional significance of CDO in the 
intestine and the effects of dietary sulfur amino acids (SAA) on CDO expression in the intestine. 
This was done by examining small intestine and colon from CDO knockout (KO) and wild type 
(WT) mice on low and high sulfur amino acid diets.  
 
MATERIALS AND METHODS 
Mouse Study.  All experimental procedures were conducted by the Stipanuk lab with the 
approval of the Cornell University Institutional Animal Care and Use Committee. Genotypes of 
pups were determined by PCR on genomic DNA samples obtained from tail snips.  Twelve WT 
(+/+) and twelve male KO (CDO -/-) mice (6 females and 6 males for each) were fed a basal 
semi-purified diet, containing adequate SAA from birth. At 7 weeks, they were placed on either a 
sulfur diet slightly low in SAA or a diet with excess SAA above the requirement level and fed 
this diet ad libitum for 1 week. Mice were killed at the end of the 1 week feeding trial at ~ 8 
weeks of age. Three female and three male mice from WT and KO mice were placed on each 
diet. 
 
CDO Immunohistochemistry. Small intestine and colon from two male and two female mice 
from each group (SAA deficient WT, SAA deficient KO, High SAA WT, High SAA KO) were 
isolated and fixed in 4% buffered paraformaldehyde for 48 hours prior to dehydration. Tissues 
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were embedded, sectioned and stained for CDO. Staining was performed by the University of 
Illinois Veterinary Biosciences Histology Laboratory. Sections were deparaffinized and brought 
to water. Antigen retrieval was performed for one hour in a steamer using Rodent Decloaker 
(Biocare). Following a rinse in deionized water, endogenous peroxidases were blocked by 
incubation in 3% hydrogen peroxide in water with agitation for 15 minutes. Sections were then 
rinsed with wash buffer, blocked with Biocare Rodent block M for 30 minutes, and rinsed briefly 
in deionized water. Sections were incubated in rabbit anti-rat CDO antibody (1:100 dilution) or 
an equivalent concentration of rabbit IgG (IgG control) for 30 minutes followed by 3 washes in 
Tris-Tween for 5 minutes each. Secondary detection was performed using Rabbit on Rodent 
HRP-Polymer (Biocare Medical) for 30 minutes, followed by three washes in Tris-Tween for 5 
minutes each, DAB chromagen (Innovex Biosciences) for 5 minutes, and 1% copper sulfate for 1 
minute. Sections were rinsed in tap water, counterstained with hematoxylin, dehydrated, cleared, 
and mounted. Stained slides were scanned at 40X using the Nanozoomer Digital Pathology 
System (Hamamatsu). 
 
RESULTS 
CDO Immunohistochemistry. As shown in Figures B.1 and B.2, positive staining was observed 
in both WT and KO mice fed a low or high SAA diet. The distribution of the staining appeared 
to be the same in all mice; in addition, both goblet and Paneth cells stained positive. Thus, there 
was no apparent difference in CDO staining between WT or KO mice or between low and high 
SAA diets. Rabbit IgG controls (Figures B.3 and B.4) did not show positive staining for CDO. 
Similar findings were observed in the duodenum and jejunum (data not shown). 
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DISCUSSION 
The results of the CDO immunohistochemistry indicate that the observed positive CDO 
staining in the intestine may be the result of the antibody cross-reacting with another protein. 
Additional studies will be performed to determine whether this is the case or if there is some 
issue with the KO mice that is leading to positive CDO staining. 
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